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Egyptian Hypertension GuidelinesAbstract81This is the third version of the Egyptian Hypertension Society (EHS) Guidelines. The guidelines were developed by a working
group of 28 members, including cardiologists, nephrologists and internal medicine specialists, who were divided into 6 writing
groups and an implementation group. Members reviewed the recent world literature as well as other national and international
guidelines. The working groups had a number of meetings over a period of one and half year, before ﬁnalizing the document.
The Egyptian guidelines were based upon two principles: 1. Address practical issues, 2. Cost containment. They stressed the need
for frequent ofﬁce visits and careful measurement of blood pressure before making a diagnosis of hypertension. Higher threshold
for diagnosis of hypertension (150/95 mmHg) was recommended. Ambulatory blood pressure monitoring (ABPM) was indicated
in a selected group of patients. Laboratory work-up was kept to the minimum particularly when resources and facilities are limited.
The need for lifestyle modiﬁcation (LSM), controlling obesity and limiting salt intake were stressed.
Initiation of pharmacologic treatment, duration of blood pressure monitoring and frequency of ofﬁce visits were based upon
the global cardiovascular risk proﬁle, level of blood pressure and response to LSM. In low risk patients, no drug therapy is rec-
ommended when blood pressure is less than 160/100 mmHg. Shorter period of blood pressure monitoring and lower blood pres-
sure threshold (140/90 mmHg) is advised in moderate and high risk patients. In absence of compelling indications any of the ﬁve
standard pharmacologic groups (diuretics, beta blockers, calcium channel blockers, ACE-inhibitors, angiotensin receptor block-
ers) can be selected as initial therapy preferably a thiazide diuretic.
In absence of satisfactory control of blood pressure, it is recommended to ensure patient’s adherence to therapy and lifestyle
changes and that he is not taking pressor medications. Obstructive sleep apnea (OSA), white coat hypertension, inadequate diure-
tic therapy and secondary forms have to be considered as causes for resistant hypertension. Pharmacologic therapy should be mod-
iﬁed according to the presence of chronic kidney disease, diabetes, coronary artery disease, heart failure and severity of
hypertension. The guidelines addressed management of hypertension in special groups such as obese subjects, the elderly, pregnant
women, hypertensive emergencies and patients with valvular heart disease.
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Problem of Hypertension in Egypt
Data from the Egyptian National Hypertension Project (NHP) [1–7] showed that hypertension is common among Egyptians. In
the years (1991–1993), 26.3% of adult Egyptians have high blood pressure. More than 50% of individuals older than 60 years
suffered from hypertension. At present, if the same prevalence rates did not change, it is predicted that with an Egyptian popu-
lation of more than 80 millions, there are approximately 15 millions with hypertension and about 7 millions will be in need of
lifelong drug treatment and regular follow-up. The problem is complicated by the low awareness rates, only 38% of hypertensive
Egyptians were aware of having high blood pressure, only 24% were receiving treatment, whereas control rates (<140/90 mmHg)
were 8%. Other cardiovascular risk factors namely hypercholesterolemia, increased LDL-cholesterol, low HDL-cholesterol,
hypertriglyceridemia, diabetes, impaired glucose tolerance and obesity were present in 60% of hypertensive patients [8]. Target
organ damage was present in patients with more than stage I hypertension (P160/100 mmHg), e.g. ECG-LVH in 20%, coronary
artery disease (CAD) 16%, systolic heart failure in 5% and renal failure in 3.2% [9]. Egyptians have one of the highest mortality
rates secondary to CAD worldwide [10,11]. Hypertension is an established major risk factor for CAD.
These epidemiologic data underscore the need for developing national hypertension guidelines aiming at improving the rates of
awareness, treatment and control of hypertension with the ﬁnal goal of preventing or delaying target organ damage, hypertensive
complications, cardiovascular and renal events and decreasing morbidity and mortality.
Because of its high prevalence, the treatment of hypertension puts economic pressure on Egyptian economy. Drug cost is the
major determinant of cost of care, responsible for around 80% of total cost of hypertension care within the ﬁrst year of treatment
[12,13]. In Egypt, the drug cost of hypertension (total antihypertensive market) during the year 2011 was more than one billion
Egyptian pounds, a dramatic increase from 600 millions in 2007 [14].
In view of Egypt’s limited ﬁnancial resources and the limited government spending on health which equals annually 42 USD per
capita (year 2008), while total annual/capita expenditure on health is 124 USD compared with 3925 USD in USA [14], guidelines
should give priority to cost of care. Furthermore, more than 58% of spending in Egypt on health care is out of pocket [14]. Choices
must be made as to how limited budget is spent. Therefore, countries with limited resources can not treat everyone with BP beyond
the deﬁned threshold stated in the international guidelines. A higher threshold of >150/95 mmHg for initiation of therapy might
be considered and priority should be given to high risk patients. On the other hand, drugs of ﬁrst choice should be the least expen-
sive such as thiazide diuretics, beta adrenergic blockers and generic forms. Patients will not adhere to drugs that they can not
afford.
Problem of Hypertension Diagnosis
Diagnosis of hypertension depends upon accurate BP measurement and repeated BP readings. An accurate measurement will
depend upon the equipment, technique, and approach whether ofﬁce, home or ambulatory BP monitoring (ABPM). Repeated
readings are taken through multiple ofﬁce visits, repeated home measurements or 24 h ABPM.
Accurate measurement requires a well calibrated machine and a trained observer familiar with the details of the technique and
precautions taken when checking BP. Many doctors have no formal education on how to measure BP accurately. Ignorance
regarding cuff selection and application, incorrect cuff positioning and rapid cuff deﬂation rate, inadequate rest period, digit bias
and lack of repeated measurements will provide inaccurate readings. Faulty equipment – sphygmomanometer (mercury and aner-
oid) will give wrong numbers. A study [15] showed that 44% of the aneroid sphygmomanometer used in hospital setting and 61%
of them used in private medical practices were found inaccurate [15]. Lack of calibration and maintenance of the aneroid sphyg-
momanometer makes them highly doubtful for routine use in medical practice, unless maintenance and calibration is implemented.
Blood pressure variability is an important limitation of casual BP ofﬁce readings. The great diurnal variability inherent in BP
behaviour, makes ofﬁce measurement of limited diagnostic value. There is a need for repeated BP measurements before diagnosing
hypertension. A single BP measurement would over-diagnose hypertension in 20–30% of cases [16,17]. Many people with current
diagnosis of hypertension might not in fact have hypertension. Routine BP values obtained in the ofﬁce are generally higher than
high quality research readings [18]. Blood pressure readings by primary care physicians tend to be higher than what it would be if
measurements guidelines were strictly adhered to [18].
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is a gap between ofﬁce and ABPM control. BP control is underestimated at the ofﬁce (52% vs. 24%) [19]. The numbers of patients
starting antihypertensive treatment could be reduced by 25% if ABPM is used instead of clinic blood pressure for diagnosis [20].
There is uncertainty around the current BP cut-off point (140/90 mmHg) leading to a huge number of people being misdiag-
nosed of having and not having hypertension. Over-diagnosis exposes people unnecessarily to considerable risk of adverse drug
reactions.
The choice of a target BP < 140/90 mmHg regardless of underlying cardiovascular risk, intensity of treatment and underlying
disease severity may not be a correct policy. Over-treatment and diastolic hypotension have been shown to be associated with
worse cardiovascular outcomes [21,22].
The cutoff point for normal BP in the ‘‘real world’’ should be < 150/95 mmHg and not the value <140/90 mmHg derived from
research studies [18]. Patients at low absolute risk may be exposed to potential side effects of a treatment for little or no therapeutic
beneﬁt.
The decision to treat or monitor without treatment should be based on patient global CV risk. Low-risk patients have a lower-
chance of gaining beneﬁt from treatment. These patients should be given lower priority for treatment when resources are limited.
Need for National Hypertension Guidelines
Physicians in many countries treat hypertension according to their daily experience, drug industry promotion, limited information
from medical school and random scientiﬁc meetings and publications. In absence of science based evidence and clear guidelines,
patients will be mismanaged with irrational use of resources, over and under diagnosis, over and under treatment, exposure of
patients to unnecessary laboratory procedures and unnecessary lifelong therapy. Different national and international organiza-
tions developed hypertension guidelines based, in the majority, on scientiﬁc evidence [23], though there are areas of agreement and
disagreements. More importantly guidelines developed for rich industrial countries may not be applicable in developing and third
world countries with a different health care system, lifestyle and dietary habits, genetic and ethnic background.
There is a need for practical guidelines designed speciﬁcally for use in resource-poor settings in place of the complex and largely
impractical international guidelines developed for higher income countries.
The need for national Egyptian guidelines should not be underestimated. This is the third version of guidelines developed by the
Egyptian Hypertension Society (EHS). The new guidelines will overcome some of the limitations of the previous one and will up-
date recommendations based upon results of recent clinical trials. A simple, clear, realistic and easy to use guidelines were the main
goal of this third version. Medical community should be familiar with guidelines and should implement them in their daily prac-
tice. Guidelines, in order to be implemented, should pay regard to the costs of treatment and should include drug affordability as
main management component. Management depends on demographic and socioeconomic factors. Other factors to be considered
when developing national guidelines include the system of medical education and the culture of the country and should make the
best use of available resources.
What is Special about Egyptian Guidelines
Differences from Other Guidelines
The Egyptian guidelines were based on two principles 1. Address practical issues, 2. Cost containment. The main theme of the
guidelines is to help answering, whenever possible, the main questions which the doctor faces when he decides that his patient has
high blood pressure. Examples are: is his patient truly hypertensive- not simply white-coat or isolated ofﬁce hypertension? Does he
need drug therapy? When to initiate and how to select initial therapy? How to monitor and follow-up? What to do if there is
unsatisfactory response to therapy?
Because of limited resources, cost consideration received great priority aiming at the most cost-effective approach in hyperten-
sion management. These inﬂuence guidelines preparation and make some issues different from other guidelines. The following
areas might be different and not in complete agreement with other guidelines.
1. Blood Pressure Measurement and Diagnosis of Hypertension
More frequent ofﬁce visits and a larger number of blood pressure readings are needed before making a diagnosis of hyperten-
sion. The threshold for diagnosis from ofﬁce readings was raised to 140/90–150/95 mmHg. Since it is not possible to apply
ABPM as a standard diagnostic approach because of economic and logistic reasons and the difﬁculty of obtaining repeated
accurate home blood pressure measurements, diagnosis will depend upon ofﬁce readings which are vulnerable to ofﬁce variabil-
ity and diurnal ﬂuctuations.
2. Limited Laboratory Work-up
Global risk assessment can be deﬁned through simple questions about history of cigarette smoking, diabetes, family history,
symptomatic CV or renal disease, measurement of body mass index and urine dipstick. This can replace, when resources
and facilities are limited, the detailed laboratory work-up recommended in international guidelines.
3. Diet and Lifestyle
To limit the need and reduce the dosage of pharmacologic agents, attention should be paid to dietary regulations and lifestyle
modiﬁcation (LSM). Excess salt intake is common among Egyptians. Salty cheeses, pickles, canned and processed food, chips,
salted nuts, ketchup and fast food should be completely avoided while limiting salt during cooking and on table. Intake of fresh
fruits and vegetables with legumes (beans) should be encouraged together with exercise and control of obesity. Tobacco should
be completely avoided; alcohol is not a problem in Egypt.
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Unless there is hypertension urgency, a long period of BP monitoring (6–9 months) is recommended before initiating a lifelong
drug therapy. Low risk patients with grade I hypertension (BP 150–159/95–99 mmHg) can be followed while on lifestyle modiﬁ-
cation without drug therapy.A higher threshold is recommended when initiating therapy (160/100 mmHg) in low and intermediate
risk groups, since BP alone is a weak predictor of future CV events. Priority of drug therapy is given to high risk patients.
5. Type of Pharmacologic Treatment
The monthly cost of drug therapy in Egypt varies from 5 to 180 Egyptian pounds when a single drug is used (monotherapy). Low
cost drugs i.e. thiazide diuretics and beta adrenergic blockers should be recommended as initial therapy unless contraindicated or
there are compelling indications for other agents. The use of generic CCB, ACEIs and ARBs should replace the expensive brand
preparations. Drugs should be affordable and match the patient socioeconomic status.
6. Measures to Improve Patient’s Compliance
Special emphasis on patient education and involvement, with prescription of simple and long acting affordable drugs while keeping
the number of tablets to the minimum.
GUIDELINES DEVELOPMENT
Panel Selection: Formation of Guidelines Working Group
There were two previous guidelines on hypertension developed by EHS in 1998 and 2004. This edition is the third in the series.
The president of the EHS, who is the guidelines main editor, selected a panel of 28 members from different specialties including
cardiology, nephrology and internal medicine. Many of these members were involved in preparation of previous guidelines.
The new EHS Guidelines Working Group had its ﬁrst meeting on May 25th 2012 at the Cairo Marriott Hotel attended by 28
members besides representatives of Ministry of Health and drug industry. During the meeting, there was a review of previous
guidelines including important international guidelines, guidelines from other developing countries and the last Egyptian guide-
lines. The review addressed how guidelines were developed and areas of agreement and disagreement between different guidelines.
Questions to be addressed in the new Egyptian guidelines were discussed. The plan of action was agreed upon. Eight different sub-
groups were formed; seven for writing and one for guidelines implementation. Each subgroup is led by a moderator or contact
author who will be responsible for directing the activities of his group and for reporting to the EHS during future meetings. A
writing group and an advisory board were selected from working group members.
Identiﬁcation of Main Questions and Chapters’ Contents
During its second meeting in Cairo on 14th June 2012, the contents of different chapters were reviewed and approved. The fol-
lowing 15 questions were thought to be critical in guidelines preparation:
1. How to measure blood pressure accurately? Technique of blood pressure measurement
2. How many measurements? And how frequent ofﬁce visits?
3. What to do about blood pressure variability?
4. How to assess CV risk?
5. When to initiate pharmacologic treatment?
6. Which drug to choose as initial therapy?
7. When to see patient again?
8. When to change medication?
9. How to improve compliance?
10. What to do when there is lack or unsatisfactory blood pressure control?
11. What is the role of non-pharmacologic treatment?
12. How to manage a hypertensive emergency?
13. How to manage secondary hypertension?
14. How to monitor antihypertensive therapy?
15. How to manage hypertension in the elderly, during pregnancy and in adolescents?
Guidelines were grouped in 6 chapters under the main headings of:
1. Blood pressure Measurement- Hypertension diagnosis.
2. Evaluation.
3. Lifestyle modiﬁcation.
4. Pharmacologic treatment.
5. Hypertension associated with other diseases.
6. Hypertension in special groups.
A seventh chapter was devoted to algorithm.
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The members reviewed available evidence from world literature and other national and international guidelines. The following
guidelines were reviewed:
1. American: (JNC VII): 2003
2. Australian: 2008
3. Canadian 2011, 2012
4. Egyptian: 2004
5. European (ESC/ ESH): 2007
6. Indian: 2007
7. Japanese: 2009
8. Latin America: 2009
9. Malaysian: 2008
10. NICE (British): 2011
11. Sub-Saharan Africa (SSA): 2003
12. WHO/ISH: 2003
13. South African Hypertension Guideline 2011The Final Document
The ﬁnal document was sent to approximately 600 doctors mainly internists and general practitioners and to a group of experts
from university professors with a check list for feedback and comments. Also guidelines with the check-list were put on EHS
website for feedback and comments from medical community. The results of the doctors and experts’ checklist survey were re-
viewed and the ﬁnal document was modiﬁed accordingly.
The ﬁnal draft of the guidelines, taken into consideration the comments and feedback from medical community was approved
by all working group members.
Steps in Guidelines Development
1. Panel selection: formation of guidelines working group– A panel of 28 members from different specialties.2. Panel 1st meeting- May 25, 2012 (Cairo, Marriott)
– Formation of 7 writing groups and GL implementation group.
– Identiﬁcation of main questions to be addressed and approval of plan of action.3. Panel 2nd meeting- June 14, 2012 (Cairo, Marriott)– Review and approval of individual chapters’ contents.
– Appointment of chapters’ main authors.4. Preparation of the preliminary draft by the writing group
5. Review of the preliminary draft
– Two-day meeting in Alexandria (11-12 October 2012).
– Assignment of separate reviewer to each chapter.6. Preﬁnal document: Cairo meeting (22-23 November 2012).
 Revised draft read and discussed by writing group members.7. Preparation of provisional ﬁnal document: Luxor meeting (19-21 December 2012)
 All chapters read: provisional approval by WG members.8. GL central review committee meeting: 21 March 2013
 Agreement on unsettled questions.
 Approval of all chapters.
 Preparation of the education program.9. Medical community feedback Provisional ﬁnal document distributed to about 600 doctors.
 Checklist survey.10. Review of doctors checklist survey by central review committee & preparation of the ﬁnal document
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Panel Selection: Guidelines Working Group
Identification of Main Questions and Areas to be addressed
Review of Available Evidence
a. Literature b. Other Guidelines
Preliminary Draft
Preliminary Draft Revision
Guidelines Review
Guidelines Approval by Writing Group
Review of Guidelines by Health Professionals
Final Document
Guidelines Implementation
SUMMARY OF RECOMMENDATIONS
BP Measurement and Diagnosis of Hypertension
A. Diagnosis of HT
1. Details of BP measurements at ofﬁce according to guidelines should be followed. All necessary precautions are taken in order to
obtain accurate readings.
2. At ofﬁce measure BP at least 3 times, 30–60 seconds apart after resting quietly 3–5 min. Use the lower of the last 2 measurement
to diagnose HT. If the initial readings are high (>150/95 mmHg), have the patient rest for 5 min and repeat measurement.
3. If all BP measurements are 150/95 mmHg or higher, to conﬁrm the diagnosis of HT choose one or more of the following:
a. Repeat ofﬁce BP measurements 3–5 times over 2–3 months depending on BP level.
b. Offer 24 h ABPM and the use of the average daytime BP.
c. Home BP monitoring, take as many measurements as possible preferably more than 14 measurements over one week.
4. Encourage the introduction of ABPM and automated BP measurement equipments to the medical community and its use in
diagnosis of hypertension.
B. Cutpoints for diagnosing HT
1. Routine clinical practice: at ofﬁce 140/90-150/95 mmHg
2. Daytime: ABPM: P 135/85 mmHg
3. Average home BP readings: P 135/85 mmHg
Evaluation
1. With optimal care check urine sediment and blood for sugar, electrolytes, lipid proﬁle, urea, creatinine and ECG in all patients.
2. Pay more attention and rely on detailed history and physical examination.
3. Use simpliﬁed risk stratiﬁcation method when resources are limited based upon:
– Age – Smoking – Diabetes (history and urine dipstick) – BMI
– Associated clinical conditions.
4. Global risk proﬁling depending upon number of RFs, TOD and symptomatic CVD to categorize patients into: low, moderate,
high and very high risk.
5. Detailed laboratory evaluation is recommended in truly resistant hypertensive patients and when suspect secondary
hypertension.
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1. Details of dietary instructions should be explained to the patient preferably in writing.
2. Salt restriction (<5 gm/day) is essential particularly in elderly, diabetics and CKD. List of food items rich in salt should be
available in doctors’ ofﬁces.
3. Weight reduction, smoking cessation and increased physical activity should be stressed in every ofﬁce visit.
4. Adherence to LSM should be monitored.
5. LSM is recommended in all patients before and during therapy.
Pharmacologic Treatment
1. Drug therapy is life-long and should be considered after failure of LSM to lower BP and if global CV risk is high.
2. In absence of speciﬁc or compelling indications for a particular antihypertensive drug, low dose thiazide diuretics are recom-
mended as initial therapy particularly in elderly patients. Patient’s socioeconomic status, drug affordability, doctor’s experience
will inﬂuence drug choice.
3. Beta adrenergic blockers (BB) are recommended in young patients with hyperdynamic heart and in the presence of coronary
artery disease or speciﬁc indications for BB.
4. Calcium channel blockers (CCBs) are recommended in elderly patients, in presence of angina, excessive BP variability or mod-
erately severe hypertension.
5. RAS blockade (ACEIs and ARBs) are recommended in diabetic patients, proteinuria, presence of TOD, associated CV or
CKD.
6. Combination therapy (2 or more drugs) is initiated in moderate and severe hypertension and in high risk patients.
7. Gradual reduction of BP and careful titration of drug dosage is essential.
Treatment of Hypertension Associated with CV, Renal Disease and Diabetes
1. Target BP is lower (<130/80 mmHg) in patients with heart failure, aortic aneurysm, CKD or diabetes with gross proteinuria.
2. BB ± CCB are indicated in patients with angina.
3. BB and RAS blockade after MI.
4. RASB + diuretics in patients with HF, CKD and diabetes.
Hypertension in Special Groups
1. Secondary forms of hypertension (renal artery stenosis, renal parenchymal disease, endocrinal hypertension, coarctation of the
aorta) are suspected in hypertension at young age (<20 years old) or new onset HT above the age of 50 years, in symptomatic
(sweating, headache, abdominal pain, weakness, etc) and difﬁcult to control hypertension. Aortic coarctation is suspected when
hypertension in young associated with weak and delayed femoral arterial pulse.
2. Factors contributing to resistant hypertension include white coat hypertension, inadequate therapy, lack of patient’s compli-
ance, failure of correction of obesity, sleep apnea, intake of pressor drugs and excess salt intake. If loop diuretics and spirono-
lactone in addition to adequate dose of triple pharmacologic therapy fail, consider secondary forms. ABPM and details of
laboratory evaluation is needed in this group.
3. Hypertension in the elderly is characterized by excess BP variability, postural changes, white coat effect, sensitivity to salt intake
and associated co-morbidities. Diuretics and CCB are the drugs of ﬁrst choice.
4. Hypertensive emergencies require hospitalization, parentral therapy and arterial pressure monitoring. They include severe
hypertension associated with life threatening organ damage, examples are hypertensive encephalopathy, aortic dissection, acute
left ventricular failure, brain infarction, intracerebral and subarachnoid hemorrhage. The recommended parental drugs are
sodium nitroprusside, labetalol and nitroglycerin.
BLOOD PRESSURE MEASUREMENT
DIAGNOSIS OF HYPERTENSION
 BP must be measured in a standardized fashion using a properly validated, well maintained and recently calibrated device.
 Blood pressure is variable. The diagnosis of hypertension should be based on multiple BP measurements taken on several sep-
arate occasions.
 Cut-off point for deﬁning hypertension during ofﬁce measurement is 140/90–150/95 mmHg, while for average home readings
and for daytime ambulatory blood pressure (ABP) is 130/85 mmHg.
 End organ disease and CV event rates correlate more closely with ABP than clinic measurements [24].
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Blood pressure can be measured by a mercury sphygmomanometer, aneroid sphygmomanometer, auscultatory or oscillometric
semi-automatic devices and automated devices.
 Wrist devices should not be used (for a list of validated BP measuring devices, see: www.bhsoc.org).
 The mercury sphygmomanometer remains the gold standard against which new BP monitor accuracy is judged.
 Aneroid manometers and new devices should be calibrated regularly.
 Digital devices include: Automatic, semiautomatic and manual monitors.
Technique of BP Measurement by Sphygmomanometer
 The blood pressure should be measured in both arms in ﬁrst visit while the patient is sitting with back supported or while lying
ﬂat on his back. Urine voided if needed. No food intake, coffee or smoking for 2 h before the procedure. Talking should be
avoided for 5 min prior and during measurement.
 Remove tight clothing, ensure arm is relaxed and supported at heart level.
 Use cuff of appropriate size. BP measuring cuff bladder should cover 80% of the arm circumference of the patient. Larger cuffs
are needed for obese subjects and smaller ones in pediatrics.
 Wrap the cuff tightly around the arm. The edge of the cuff should be 3 cm above the elbow crease.
 Inﬂate the cuff till disappearance of the radial pulse. Slowly deﬂate the cuff till reappearance of the radial pulse. The level at
which the radial pulse starts to reappear is the palpable systolic blood pressure.
 Put a stethoscope over the brachial artery. Inﬂate cuff to 20–30 mmHg above palpated systolic BP.
 Lower column slowly, by 2 mmHg per second or per beat.
 Measure systolic pressure as ﬁrst appearance of sounds (Korotkoff I) and diastolic pressure as disappearance of sounds
(Korotkoff V). The sudden reduction of sound (Korotkoff IV) is read as diastolic blood pressures when there is a wide pulse
pressure (anemia, aortic incompetence, etc . . .) or when sounds continue to zero blood pressure. Read BP to the nearest
2 mmHg.Precautions to obtain correct BP reading
1. Choose the correct cuff size.
2. Avoid placing the cuff over clothes.
3. Arm must be at heart level.
4. Patient should rest quietly for 3–5 min before measurement in a quite room with comfortable temperature.
5. Avoid talking during measurement.
6. No caffeine or cigarette smoking at least 1 h before procedure.
7. Bladder should be evacuated.
8. Palpate radial pulse before auscultatory measurements (to avoid the auscultatory gap).
9. Do not deﬂate the cuff too quickly (2 mmHg/beat).
10. Do not re-inﬂate the cuff to repeat measurements before it has fully deﬂated.
11. Take more than one measurement.
12. If there is a difference of more than 10 mmHg between two measurements take more measurements.Standing BP Measurement
 The standing blood pressure should be taken in the following situations:
1. First visit evaluation.
2. Elderly patients (above 60 years).
3. Diabetic patients of any age.
4. Patients with postural symptoms; dizziness, light headedness or faintness.
5. Intake of drugs that can produce postural hypotension
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 In the standing position, the arm should rest supported on either a high table, the shoulder of the examiner or in the armpit of
the examiner, depending on the relative height of the patient and the examiner.
 Orthostatic (postural) hypotension is diagnosed byP20 mmHg drop in systolic blood pressure and/orP10 mmHg drop in dia-
stolic blood pressure within 2 min of standing up.METHODS TO DIAGNOSE HYPERTENSION
Ofﬁce BP Measurement
 Ofﬁce measurement is the routine method for screening and follow-up of blood pressure. The current cut-off point of diagnos-
ing hypertension in daily practice is based on ofﬁce measurement.
 Mercury and digital (automated) blood pressure machines can be used in ofﬁce measurements, but only validated devices are
allowed. Mercury sphygmomanometer gives the most accurate BP reading.
 All sphygmomanometers require servicing at least once each year.
 Ofﬁce measurements correlate poorly with blood pressure measured in other settings. The cut-off point for normal blood pres-
sure in the ‘‘real world’’ should be <150/95 mmHg and not the value of less than 140/90 mmHg derived from research studies
[18].
 The selection of the cut-off point of 150/95 mmHg for diagnosis of hypertension during ofﬁce measurement is based upon the
new data which showed that this level of blood pressure corresponds with the diagnostic threshold of 135/85 mmHg taken at
daytime ambulatory blood pressure measurement [18]. This choice will avoid over diagnosis of hypertension since many people
with a current diagnosis of hypertension might not, in fact, have hypertension.
 Recent studies showed a consistent difference between awake ABP and the routine ofﬁce blood pressure greater than the nor-
mally recognized 5 mmHg (140/90 mmHg for ofﬁce blood pressure vs. 135/85 mmHg for mean awake ABP) [18,19]. Thus, BP
measured in routine clinical practice seems to be at least 10/5 mmHg higher than a research quality ofﬁce BP.
 Blood pressure readings by primary care physicians tend to be higher that what it would be if measurement guidelines were
strictly adhered to. Table 1 shows classiﬁcation of hypertension based upon ofﬁce measurements.
Home BP Measurement
 Self-measurement of BP at home is better than ofﬁce measurements as it correlates with target organ damage (TOD), it detects
white-coat and masked hypertension, it improves patient’s adherence to therapy and it is cheaper than frequent ofﬁce visits.
 Normal home BP measurement should be less than 135/85 mmHg. Measure blood pressure twice daily for 7 days and take aver-
age of the last 6 days [24].
 Home measurement should be discouraged if it causes anxiety to the patient or inducing self modiﬁcation of antihypertensive
medications.
 Home measurements should be regarded as supplementary to ofﬁce readings, not a substitute for them.
 The patient should not stop, modify or change his medication without consulting his physician based on measurements taken
outside the physician’s ofﬁce (pharmacy or home).Rationale for 150/95 mmHg
 Better correlation with clinical outcome.
 Minimize over-diagnosis of HTN in clinical practice.
 Minimize the white-coat effect on BP in general practice.
 Establish a more practical and cost-effective strategies for managing patients in a society with limited health care resources.
 The diagnostic threshold of 140/90 mmHg is neither evidence-based nor universally accepted. At the 17th World Conference
of Hypertension League Council (1997), 13 out of 27 national hypertension societies stayed with 160/95 mmHg [25].
 The distress about having hypertension wrongly diagnosed and possibly requiring unnecessary life-long drug therapy may
lead to development of anxiety symptoms, costs and adverse drug reactions without any beneﬁt.
 The threshold of 140/90 mmHg was based upon data from research studies and drug trials where BP readings were taken for
research purposes and do not actually represent routine ofﬁce measurements.
 Data derived from several large studies have equated a manual (research quality) ofﬁce BP of 140/90 mmHg with a mean
awake ABP of 135/85 mmHg [18,20,26–29]. There was a consistent difference between the mean awake ABP and the routine
ofﬁce greater than the usual recognized 5 mmHg (140/90 mmHg for ofﬁce BP vs. 135/85 mmHg for mean awake ABP)
[18,20,26–29]. BP measured in routine clinical practice seems to be at least 10/5 mmHg higher than the research-quality ofﬁce
BP.
Table 1 Deﬁnition and classiﬁcation of hypertension.
Category Systolic Diastolic
Normal < 140 And/or <90
High normal 140–149 And/or 90–94
Mild hypertension 150–159 And/or 95–99
Moderate hypertension 160–179 And/or 100–109
Severe hypertension P180 And/or P110
Isolated systolic hypertension P160 And <90
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 The idea is applying an automatic BP measuring device to patient while allowing him to conduct normal life activities. The
machine provides information on 24-h blood pressure as well as on mean values over more restricted periods such as the
day, night or morning through checking BP every 15–30 min.
 ABP is the best method to diagnose hypertension but is not used for long-term follow-up. The major limitations are the cost and
inconvenience to patient.
 Advantages of ABPM over ofﬁce measurement [24,29–31]:
1. Better correlation to end-organ damage.
2. Better prediction of cardiovascular events.
3. Better assessment of degree of BP reduction by antihypertensive medications.
4. No white coat hypertension.
 Recent guidelines (NICE 2011) recommend treatment decisions based on ABPM [32].
 Normal ABPM averages are less than 135/85 mmHg for daytime readings and less than 120/70 mmHg for nighttime readings
and less than 130/80 mmHg for 24 h [24,33].
 Currently the ABPM is not widely available in Egypt. The equipment is expensive and the procedure is inconvenient to the
patient.Blood Pressure Variability
 Blood pressure is characterized by large spontaneous variations from time to time in a hypertensive patient during the day and
between days, months and seasons. Therefore the diagnosis of hypertension should be based on multiple blood pressure mea-
surements, taken on separate occasions over a period of time [34].
 BP and heart rate should drop by 10–15% during sleep, a condition known as ‘‘dipping’’. Non dippers are at higher risk of
future cardiovascular events [34–36].
 BP variability can be evaluated through ABPM, repeated home BP and ofﬁce measurements. It is assessed through estimation
of the standard deviation of mean blood pressure measurements.
 Enhanced BP variability independently contributes to target organ damage and the cardiovascular complications of
hypertension.
The diagnosis of hypertension should be based on at least 3 blood pressure measurements 30–60 s apart after resting for at least
5 min and on repeated ofﬁce visits. If there is a difference of P10/5 mmHg between readings, take more measurements, take the
lowest reading of the last 2 measurements. If the initial readings are high (>150/95 mmHg), have the patient rest for 5 min and
repeat measurement.
Number of Ofﬁce Visits and Interval Between Visits will Depend upon the Level of BP and Patient’s Risk Proﬁle.
 For mild hypertension, the repeated measurements should be made over the subsequent 2–3 months. For moderate or severe
hypertension, and/or evidence of target organ damage further assessments should be made over a shorter period e.g. 3–4 weeks.
 In low-risk patients (no other cardiovascular risk factors, TOD or associated cardiovascular or renal disease):
– If BP is >180/110 mmHg, exclude panic attack or severe anxiety and repeat measurements within 30 min at ofﬁce. If blood
pressure is persistent >180/110 mmHg, diagnose hypertension.
– If BP is 160–180/100–110 mmHg, check blood pressure at least 3 times within 4–8 weeks to conﬁrm hypertension.
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 In some patients ofﬁce blood pressure is persistently elevated while daytime or 24-h blood pressure, or home blood pres-
sure, are within normal range. This condition is known as ‘white coat hypertension’ or isolated ofﬁce hypertension.
 It is present in 20–35% of patients who have elevated ofﬁce BP [17,30].
 It is more common in grade 1 (mild) hypertension, in females, at older ages, and in hypertension of recent onset [34].
 When suspecting white coat hypertension, the physician should ask for a home or ambulatory BP measurements.
Masked Hypertension or Isolated Ambulatory Hypertension
 Clinic BP is normal while ambulatory BP is high.
 Masked hypertension should be suspected if TOD progresses or does not resolve, despite BP control in the clinic.
 It is not a benign condition and is associated with increased risk of future cardiovascular events [30,37].One or Both Arms?
 BP should initially be measured in both arms as a signiﬁcant number of patients, particularly the elderly, have large differ-
ences between arm (>10 mmHg) and the arm with the highest value used for subsequent measurements.
 Use the same arm and same body position in the follow - up measurements.
Rhythm Disturbances
 With an irregular pulse (atrial ﬁbrillation, frequent premature beats) take the average of four blood pressure readings or
equate systolic blood pressure with the consistent presence of sounds.
 With a profoundly slow pulse (e.g., complete heart block): slower deﬂation is needed, drop pressure extremely slowly at
about 2 mmHg/heart beat. Rapid cuff deﬂation can cause false low readings of both systolic and diastolic blood
pressure.
 Systolic hypertension is common with profound bradycardia. The clinical implication of these pressures is not known.Clinical and Laboratory Evaluation (See Table 2).
Objectives
a. Identify high risk patients
1. Detect other cardiovascular risk factors.
2. Assess target organ damage.
3. Diagnose associated cardiovascular or renal disease.
b. Identify secondary causes of hypertension and comorbid conditions.Laboratory Tests
 Essential (in all patients):
a. Urine: dipstick for protein, blood, sugar
b. Blood tests: sugar, creatinine
 Recommended (if facilities are available)
a. Blood lipid proﬁle: total cholesterol, LDL, HDL, triglycerides
b. Uric acid
c. Serum potassium
d. Hemoglobin
e. ECG
f. Special investigations in resistant or suspected secondary forms of hypertension (refer to Chapter # 6).
g. Optic fundus in patients with severe hypertension.
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In most patients, uncomplicated essential hypertension causes no symptoms.
Physician should inquire speciﬁcally about:
1. Previous levels of high blood pressure with and without treatment.
2. Symptoms of target organ damage: shortness of breath, chest pain, edema of lower limbs, neurological complaints (TIA,
stroke).
3. Current drug intake: antihypertensive and other drugs (e.g. contraceptive pills, non-steroid anti-inﬂammatory agents,
etc.).
4. Co-morbid conditions (diabetes, bronchial asthma, gout, migraine, CKD, depression, sexual dysfunction, etc.).
5. Family history of hypertension, diabetes, coronary artery disease, stroke or renal disease.
6. Life style factors: salt and fat intake, smoking, physical activity and alcohol consumption.
Clinical Examination:
 Body weight and height. Waist circumference.
 Pulse: rate, irregularity, equality in 4 limbs.
 Skin and face: pallor, pufﬁness, rash
 Neck: carotid bruits, JVP, thyroid.
 Heart: LVH, gallop, valvular disease.
 Chest: pulmonary crepitations, COPD, bronchial asthma.
 Limbs: edema, pulsations
 Abdomen: masses, tenderness, organomegaly, abdominal bruits, aortic pulsations.
Optional Tests
More extensive investigations are indicated in the following conditions:
1. When secondary forms of hypertension are suspected (see Chapter # 6).
2. To determine the signiﬁcance of mild elevation of BP by screening for target organ involvement.
3. When symptoms are suggestive of target organ damage or associated cardiovascular or renal disease.
Extensive investigations include
1. Echocardiography.
2. Abdominal ultrasound.
3. Duplex ultrasound for carotid arteries.
4. Ambulatory blood pressure recording.
5. Goal-oriented testing for suspected secondary hypertension.Table 2 Frequency of Investigations.
Investigation Clinic frequency
Body weight Every visit
Height First visit
Waist circumference Every visit
Urine dipstick: for protein, blood and sugar First visit, yearly if normal, repeat at next
visit if abnormal on ﬁrst visit
Blood tests
– Creatinine
– Potassium
– Glucose (fasting)
– Random total cholesterol
Yearly if normal
Yearly if normal, every 3–6 months if taking
diuretics and ACE blockade
Yearly if normal
Yearly if normal
ECG Yearly if normal
Modiﬁed after South African Guidelines 2012 [38]
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Echocardiography
Echocardiography is superior to radiography and electrocardiography in detection and quantiﬁcation of left ventricular hyper-
trophy [39].
Indications
Echocardiography is not a routine test and is recommended if there is ECG abnormalities or symptoms or signs of cardiovas-
cular disease.
Ambulatory Blood Pressure Monitoring(See chapter on BP measurement)
Indications [40]
1. Suspected white coat hypertension (isolated ofﬁce hypertension).
2. Suspected masked hypertension.
3. Resistant hypertension.
4. Mild hypertension with target organ damage.
5. Symptoms suggestive of hypotension.
6. Paroxysmal hypertension or excessive ofﬁce BP variability i.e. marked variability of BP readings during and between ofﬁce
(ofﬁce to ofﬁce) visits.
Assessment of Cardiovascular Risk Proﬁle
The risk of cardiovascular disease in patients with hypertension is determined not only by the level of blood pressure but also by
the presence or absence of target organ damage, other cardiovascular risk factors, associated clinical conditions and diabetes.
Cardiovascular Risk Factors
1. Diabetes mellitus: fasting plasma glucose >126 mg/dl, random plasma glucose >200 mg/dl or receiving treatment of dia-
betes or HbA1c > 6.5 with symptoms of polyurea and polydypsia [41].
2. Males >55 years or Females >65 years.
3. Total S-Cholesterol > 240 mg/dl, HDL-C <40 mg/dl or LDL-C >160 mg/dl.
4. Cigarette smoking.
5. Obesity (BMI > 30 kg/m2)
6. Serum creatinine > 2 mg/dl.
7. Metabolic syndrome: combination of abdominal obesity (waist circumference >93.5 cm in men and >92.5 cm in women)
[42], impaired glucose tolerance (fasting blood sugar 110–126 mg/dl), increased plasma triglycerides (> 200 mg/dl) and low
HDL-C (<40 mg/dl).
8. Family history of atherosclerotic cardiovascular diseases in a ﬁrst degree relative (parents, siblings or brothers) before the
age of 40 years in males and 50 years in females.
Silent Target Organ Damage
– Left ventricular hypertrophy (LVH):
a. ECG criteria (Sokolow-Lyon SV1 + RV5 or V6 > 35 mm, tall R in AVL> 11 mm) [43].
b. Echo criteria (wall thickness P12 mm or LVMI in males P125 gm/m2 or in females P110 gm/m2 [44]
– Carotid bruits
– Proteinuria: microalbuminurea 30–300 mg/24 h
– Increased serum creatinine >1.4 mg/dl in females and >1.5 mg/dl in males
– Optic fundus changes: >grade I retinopathy
Cardiovascular Risk Categorization
Depending upon the global risk proﬁling, hypertensive patients can be categorized into four groups:
Risk Group A (low risk): patients with no other cardiovascular risk factors, no target organ damage or associated atheroscle-
rotic cardiovascular diseases.
Risk Group B (moderate/intermediate risk): patients with additional 1 or 2 risk factors (not including diabetes) but with no
target organ damage or associated atherosclerotic cardiovascular diseases.
Risk Group C (high risk): patients with diabetes, target organ damage or associated asymptomatic atherosclerotic cardiovas-
cular diseases or patients with 3 or more risk factors or a very high level of a single risk factor.
Risk Group D (very high risk): Patients with symptomatic established cardiovascular or renal disease:
– Coronary artery disease (angina, MI, CABG, PCI).
– Cerebrovascular disease (stroke, TIA).
– Peripheral arterial disease.
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– Abdominal aortic aneurysm.
– Renal failure: serum creatinine >2 mg/dl.
Identiﬁcation of High Risk Individuals
The ﬁnal aim of controlling hypertension is prevention of stroke, myocardial infarction, renal failure and heart failure. Preven-
tive strategies, including lifestyle modiﬁcation, will be most effective when they are targeted to individuals with a high risk of car-
diovascular disease. High risk refers to a high probability of developing a CV event in the coming 5 or 10 years.
LIFESTYLE MODIFICATION
 Reduce weight if overweight by 5 kg over 4–6 month or achieve healthy body weight.
 Regular physical exercise of brisk walking (30–60 min) at least 5 days per week.
 Reduce salt intake to less than 5 g of sodium chloride/day.
 Encourage intake of healthy diet rich in fresh fruits, vegetables, and low fat dairy products with a reduced content of saturated
and total fat.
 Stop smoking.
 Control stress with regular physical activity, behavior modiﬁcation, change home and work environment conditions, if possible.
 Non-pharmacological interventions (lifestyle modiﬁcation) are beneﬁcial in reducing high blood pressure and a variety of other
cardiovascular risk factors. They may also reduce the dosage requirements of antihypertensive drugs.
 Lifestyle modiﬁcation should be recommended in all hypertensive patients initially and as an adjunct to drug therapy.
Weight Reduction
Recommendations
 All hypertensive patients should maintain normal body weight (body mass index of <25 kg/m2).
 A reasonable goal is to decrease body weight by 10% or 5 kg over 4–6 month period. General guidelines to reduce calories:
– Prepare all food without addition of butter, margarine, fat, oil or sugar.
– Limit servings to 3 meals a day and one small snack in the afternoon.
– Avoid continuous eating or snacking.
– Limit portion sizes, eat slowly and increase ﬁber intake (beans and vegetables).
– Avoid high caloric foods: candy, cookies, pies, pastries, carbonated beverages (e.g. cola), nuts, chips, dried fruits.
– Avoid appetizers.
– Palm oil (rich in transfatty acids) is dangerous and should be avoided. It is present in cakes and biscuits.Reduction of Dietary Sodium
Salt Sensitivity
 Salt sensitivity (excess rise in BP in response to salt intake) is present in 40% of patients with essential hypertension [45].
 Salt sensitivity is more common in the following groups [46]:
– Elderly
– Blacks
– Insulin dependent diabetes
– CKD.
Recommendations
 Limit salt intake to less than 5 g of table salt (about 1 teaspoon) and < 3 g in the elderly (> 70 years old).
 Substitute natural foods for processed foods and keep plenty of herbs and spices on hand to ﬂavor your dishes. Use lemon,
vinegar, cumin and pepper to replace salt.
 Do not add sodium chloride to food during cooking or on table.
 Avoid use of fast foods (e.g. beef burger, pizza, chips), pickles, salty snacks, cheese, preserved meat and ﬁsh, processed cheese
and packed soups.
 Taste adaptation to reduced sodium intake occurs with time [47].
Potassium Intake
Recommendations
 Increased potassium intake reduces BP in adults with hypertension and is associated with a 24% reduced risk of stroke [48].
 Maintenance of adequate potassium intake, preferably from dietary sources, is recommended for hypertensive persons.
 A diet rich in fruits and vegetables (DASH Diet) is superior to pills or other supplements as potassium sources [49].
98 MM. Ibrahim Potassium supplements should be avoided in patients with renal insufﬁciency, or those taking potassium sparing diuretics,
ACE-inhibitors, or ARBs.Foods rich in potassium [50,51]
 Highest content (>1000 mg/100 g).
 Dried ﬁgs
 Molasses
 Very high content (>500 mg/ 100 g)
 Dried fruits (dates, prunes)
 Nuts
 High content (>250 mg/100 g)
 Vegetables: spinach, tomatoes, broccoli, winter squash, beets, carrots, cauliﬂower, potatoes
 Fruits: bananas, cantaloupe, kiwis, oranges, mangoHealthy Diet
Recommendations
 A diet that emphasizes fruits, vegetables and low-fat dairy products, soluble ﬁbers, whole grain and protein from plant sources
and low in saturated fat and cholesterol [49,51] (see Table 3 for more details).
 Because the information conveyed during the few minutes available in the ofﬁce setting is easily forgotten, it is helpful to pro-
vide educational materials, such as pamphlets, brochures, or booklets that patients can take home.Food items to be avoided in hypertensive patients [51]
– Table salt (sodium chloride)
– Baking powder
– Sodium bicarbonate
– Fried food
– Salt preserved foods
 Pickles and canned foods
 Ketchup and sauces
 Ready to eat foods (fast foods)
– Highly salted foods
 Potato chips, cheese, peanut butter
 Salted butter, salted nuts, salted ﬁsh
– Bakery products
 Biscuits, cakes, salted breads
Table 3 Dietary approaches to stop hypertension (DASH) diet [49].
Food group Servings Examples and notes
Grains 7–8/day Whole wheat bread, oatmeal, popcorn
Vegetables 4–5/day Tomatoes, potatoes, carrots, beans, peas, squash, spinach
Fruits 4–5/day Apricots, bananas, grapes, oranges, grapefruit, melons
Low-fat or fat-free dairy foods 2–3/day Fat-free (skim) or low-fat (1%) milk, fat-free or low-fat yogurt, fat-free or low-fat cheese
Meats, poultry, ﬁsh 62/day Select only lean meats. Trim away fats. Broil, roast or boil. No frying. Remove skin from poultry
Nuts, seeds, dry beans 4–5/week Almonds, peanuts, walnuts, sunﬂower seeds, soybeans, lentils
Fats and oils 2–3/day Soft margarines, low-fat mayonnaise, vegetable oil (olive, corn, canola or saﬄower)
Sweets 5/week Maple syrup, sugar, jelly, jam, hard candy, sorbet
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Recommendations
 Moderate activity such as 30–45 min of brisk walking 5–7 times/week is beneﬁcial.
 In previously inactive patients, an initial exercise program should be of a short duration (i.e. 10 min/day) of activity daily and
gradually increase to 30 min/day of low-intensity activity. Intensity can be increased as the patient’s strength and ﬁtness
improves.
 Exercise performed at home, rather than at a health club, reduces barriers of cost and travel time. Also, exercise does not need
to occur in a single session to be beneﬁcial as dividing activity into multiple, short bouts produces similar beneﬁts and can
enhance compliance.
 Use stairs instead of elevators.
Stress Management
 For hypertensive people in whom stress may be a contributing factor to blood pressure elevation, stress management by phys-
ical exercise in open air [52] or anxiolytic drugs when needed.
Caffeine
Recommendation
 It seems prudent to recommend moderation when it comes to the ingestion of caffeine containing beverages. There is little evi-
dence to suggest that habitual consumption at the current average of the equivalent of 2–4 cups of coffee per day causes an
increase in blood pressure of any clinical importance [53].
 Ingesting of larger amounts (e.g. 5–6 cups of coffee per day) should be discouraged in patients with hypertension or in those
individuals having a pre-hypertensive state.
Herbal Dietary Supplements
 Licorice consumption in excess can increase BP and should be discouraged.
 Herbal therapy (Hibiscus ) should be discouraged because there are no clinical trials to prove its efﬁcacy and safety.
Alcohol
 Those who drink should limit alcohol intake specially in the elderly and women.
Tobacco Avoidance
Recommendations
 There are various strategies that can be used to promote smoking cessation, including advice from a physician, nicotine replace-
ment therapy, behavior modiﬁcation, and smoking cessation programs.
PHARMACOLOGIC TREATMENT OF HYPERTENSION
(SEE TABLES 4–8)
 Antihypertensive drugs can be classiﬁed into 3 big categories: 1. First line or drugs of ﬁrst choice which include thiazides and
thiazide derivatives (D), beta adrenergic blockers (BB), calcium channel blockers (CCB), angiotensin-converting-enzyme inhib-
itors (ACEIs) and angiotensin receptor blockers (ARBs). There is evidence from clinical trials that drugs in this group can
improve prognosis and prevent TOD and disease progression.2. Second line or accessory drugs which include: loop and potas-
sium sparing diuretics, central sympatholytics (methyldopa and clonidine), peripheral sympothalytics, (reserpine, guanethidine),
a1 adrenergic blockers (prazosin and doxazosin) and direct arterial vasodilators (hydralazine and minoxidil).3. Drug combina-
tions combining 2 drugs from different pharmacologic groups in a single pill.
 Initiation of drug therapy depends upon the patient global cardiovascular risk proﬁle, level of BP and its response to lifestyle
modiﬁcation.
 Drug therapy should be started immediately in case of hypertensive emergencies and urgencies, otherwise a trial of non-phar-
macologic treatment (lifestyle modiﬁcation) for a period of weeks to months is recommended while monitoring BP on frequent
ofﬁce visits or at home before initiating drug treatment.
 The selection of the drug for initial treatment depends upon the presence of any compelling indications for a speciﬁc pharmacologic
group such as coronary disease, heart failure, diabetes, chronic kidney disease (CKD) or associated co-morbid conditions.
 In patients with more than mild hypertension (P 160/100 mmHg) and high risk patients, it is recommended to initiate therapy
with a combination of two drugs.
 The BP target will depend upon the global risk proﬁle of the patient and will vary from <150/95 mmHg in low risk patients to
<130/80 mmHg in some high risk patients.
Table 4 When to Initiate Drug Therapy? Blood pressure threshold and duration of initial monitoring.
Population LSM Duration SBP DBP
Low risk patients 3–6 m 160 100
Moderate and high risk (P2 RFs, DM, TOD, CKD) 3–6 w 140 90
Very high risk patients* 1–2 w 130 80
Elderly 3–6 w 150 95
 m: month, w: week, LSM: lifestyle modiﬁcation.
* Associated CV disease: CAD, cerebrovascular, HF, peripheral arterial disease and aortic aneurysm. CKD with proteinuria >1000 mg/24 h
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modiﬁcation and regular BP monitoring is the recommended policy.
INITIATION AND MONITORING OF DRUG THERAPY
The Decision To Initiate Drug Therapy for High Blood Pressure Should Not Be Taken Lightly Since Once Initiated, therapy
should continue indeﬁnitely, as there is no cure from established essential hypertension, except in the unusual instances after devel-
oping a large MI, stroke or Addison’s disease. Discontinuation of drug therapy leads to re-elevation of high blood pressure within
days to months and is asymptomatic.
Initiation of drug therapy depends upon:
1. Level of blood pressure.
2. Global risk proﬁle of patient.
3. Response to non-pharmacologic treatment.
Level of Blood Pressure
 Similar to recent NICE hypertension guidelines (2011) [54], Egyptian guidelines recommends a differential treatment ini-
tiation threshold where pharmacologic treatment is initiated If BP is >160/100 mmHg (home BP >150/95 mmHg) in low
risk patients or if BP is > 140/90 mmHg (home BP >135/85 mmHg) in patients with target organ damage, cardiovascular,
renal disease, diabetes or multiple risk factors.
TIMING OF INITIATION OF DRUG THERAPY
1. Immediate: On First Ofﬁce or Hospital Visita. Hypertensive emergency.
b. BP >210/120 mmHg on 3 consecutive measurements 2–3 min apart after excluding a panic attack.
c. BP >180/110 mmHg on 3 consecutive measurements (2–3 min apart) in presence of: TOD: LVH (ECG, clinical, echo), proteinuria, elevated serum creatinine (>1.5 mg/dl in males, >1.4 mg/dl in females),
optic fundus >gr I retinopathy, aortic aneurysm, carotid bruits.
 Symptomatic CVD (CAD, HF), stroke, transient ischemic attack (TIA), peripheral arterial disease (PAD), chronic kidney
disease (CKD).
If suspect panic attack11 Panic attacks [55] are episodes of intense fear or apprehension that are of sudden onset and of relatively brief duration. Panic attacks usually
begin abruptly, reach a peak within 10min, and are mainly over within 30min. Panic attacks can be as short as 15 s, or can be cyclic, lasting for an
extended period, sometimes hours, accompanied by at least 4 of the following 13 somatic and cognitive symptoms:
–Shortness of breath.
–Dizziness.
–Palpitations.
–Trembling.
–Sweating.
–Feeling of choking.
–Nausea/abdominal distress.
–Depersonalization.
–Paresthesias.
–Flushes/chills.
–Chest pain.
–Fear of dying.
–Fear of going crazy or fear of doing something uncontrolled.
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2. Give a minor tranquilizer e.g. diazepam.
3. Do not give antihypertensive drugs unless: BP >180/110 mmHg + TOD
 If it persists >210/120 mmHg in 3 consecutive readings during the visit (30–60 min).1. Within Days To Months After 1st Ofﬁce Visit
Timing of Initiation (oﬃce visits) BP Grade Risk Category
1–3 weeks (2 visits) Grade III (severe) Moderate
Grade II (moderate) High
Grade I (mild) Very high
1–3 m (2–4 visits) Grade II (moderate) Moderate
Grade I (mild) High
3–6 m (2–3 visits) Grade I (mild) Moderate
>6 m (2–3 visits) Grade I (mild) LowBP grades: mild (150–159/95–99), moderate (160–179/100–109), severe (P180/110 mmHg)
Risk categories for hypertensive patients
– Low risk:
 No additional CV risk factors
 No TOD
 No associated atherosclerotic CV or renal disease
– Moderate or intermediate risk:
 1–3 additional CV risk factors
– High risk:
 >3 additional RFs, or TOD or DM or renal failure
– Very high risk
 Symptomatic CVD and cerebrovascular disease
Initiation of drug therapy in patients with mild hypertension (150–159/95–99 mmHg)
Depends on risk proﬁle:
– Low: Lifestyle modiﬁcation with follow-up can be the only therapy .
– Moderate: Initiate therapy after 2–3 months if BP persists? 140/90 mmHg.
– High: Initiate therapy after 2–3 weeks if BP persists? 140/90 mmHg.
– Very high: Initiate therapy within 1 week.MONITORING OF DRUG THERAPY
– Antihypertensive drugs may require a period of up to two months to achieve maximal hypotensive effect [56]. However, a
signiﬁcant reduction in BP is obtained after 2 weeks of therapy with many antihypertensive drugs particularly combination
therapy [56]. Do not change drugs at short intervals.
– Recheck blood pressure at one to two monthly intervals until blood pressure remains at target level for two consecutive
visits then recheck at 3–6 month intervals depending upon the risk proﬁle
– In absence of blood pressure response (fall in systolic blood pressure by 10 mmHg and diastolic blood pressure by
5 mmHg) in mild and intermediate risk groups after one to two months of initiation of drug therapy, add another drug
from a different pharmacologic group or use a single dose combination. In high and very high risk patients, if a satisfactory
response to the initial combination therapy after two weeks is not obtained, add a third drug or a diuretic if not initially
prescribed.
– Once blood pressure is at goal and stable, the patient should be seen usually at three- to six-month intervals to assess
patient adherence, patient satisfaction and any changes in target organ status.
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laboratory tests. Lifestyle modiﬁcations should be reviewed, reemphasized and documented annually.
– Treatment and follow-up should continue indeﬁnitely.
MONITORING OF DRUG THERAPY
Serum Potassium
– Patients receiving thiazide and loop diuretics are at increased risk of hypokalemia. Serum K estimation is recommended
particularly if patients show heart rate irregularities (PVCS), ECG abnormalities (ST, T wave changes) or on digitalis
therapy.
– Patients receiving K-sparing diuretic (spironolactone–aldactone) require regular serum K measurements because of risk of
hyperkalemia (Serum K> 5.5 mEq/l).
- Patients at increased risk of hyperkalemia include those on RAS blockade (ACEIs or ARBs), patients with renal insufﬁ-
ciency or receiving K supplements.
Serum Creatinine (see Algorithm 5)
– Serum creatinine should be estimated 2–4 weeks after initiation of RAS blockade (RASB) specially in patients with CKD,
HF or on aggressive diuretic therapy. A rise in serum creatinine up to 30% above initial level is expected in majority of
patients [57–59]. Serum creatinine levels tend to revert to initial levels within 6–8 weeks in spite of continuation of therapy
[57,58].
– If serum creatinine continues to rise on repeated measurements or if initial rise is greater than 50% stop RAS blockade and
exclude hypovolemia (following aggressive diuresis or dehydration), intake of NSAIDs, polycystic kidney disease and renal
artery stenosis [57,59]. Patients at increased risk of rise in serum creatinine are elderly patients (>65 years) and patients
with high baseline levels (>1.4 mg/dl).
– If the increase in serum creatinine is between 30% and 50 % decrease the dose of ACEIs or ARB by 50% and recheck after
4 weeks if still more than 30% discontinue RAS blockade.Table 5 Selection of antihypertensive drugs.
Class of drug Indications Contraindications Caution/limited value
Thiazide diuretics - Heart failure Gout - Pregnancy
- Elderly patients - Dyslipidemia
- Black patients - Hypokalemia
- Obese patients - Advanced RF
- Other low renin forms:
diabetes, CKD
B- Blockers - CAD - Heart block (>grade I) - Blacks
- Tachyarrhythmia - Bronchial asthma
requiring inhalation therapy
- Elderly
- Pregnancy
- Increased adrenergic activity
- Heart failure, hypertrophic
cardiomyopathy
- Symptomatic bradycardia (<50 beats/m)
- Associated: migraine, anxiety,
tremors, hyperthyrodism
ACE inhibitors/ ARBs - Heart failure - Pregnancy - S. creatinine elevation
- After MI - Diabetes - Bil renal artery stenosis - Blacks - Hyperkalemia
- Microalbuminuria
- Proteinuric CKD
- Sensitivity (angioneurotic edema) - Acute renal failure
- Target organ damage
(LVH, CV disease, PAD)
CCB - Angina
- Peripheral vascular disease
- Elderly patients
- Systolic hypertension
- Black patients
- Excessive BP ﬂuctuations
a1Blockers: Prazosin
(combined with diuretics).
- Bengin (senile) prostatic
hypertrophy
- Dyslipidemia
- Postural hypotension
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Treatment should be directed to correction of the underlying cause (e.g. anxiety, excess salt intake, pressor drugs, interruption
of treatment). Panic attacks can be associated with very high BP levels (200/120 mmHg).Blood Pressure Targets
– <150/95 mmHg in low risk patients and in elderly (>65 years).
– <140/90 mmHg:? 2 risk factors, diabetes, CKD, TOD.
– <130/80 mmHg: HF, CKD or diabetes when associated with proteinuria >1 g/24 h.Aggressive Blood Pressure Lowering
 Treating patients to lower than standard BP targets (140–150/90–95 mmHg) does not reduce mortality and morbidity in
patients with uncomplicated hypertension [60].
 No signiﬁcant beneﬁt to lower BP goals (<130/80 mmHg) for the subset of patients with diabetes or chronic renal disease
in absence of gross proteinuria >1 g/24 h) [60–62].
 Moderate control of SBP <150 mmHg may be sufﬁcient in elderly hypertensives [63].
SELECTING FIRST-LINE THERAPY
In Absence of Compelling Indications for a Speciﬁc Pharmacologic Group:
– In mild-moderate hypertension (150–179/95–109 mmHg) without TOD or symptomatic CVD, initiate monotherapy from
any of the 5 standard pharmacologic groups (diuretics, BB, CCB, ACEIs, ARBs) preferably a Thiazide diuretic. In elderly
(age >65 years) or in blacks, it is preferable to start with diuretic or CCB [64,65]. In young, particularly those with tachy-
cardia start with BB.
– In moderate or high risk patients or those with BP P180/110 mmHg, start with combination therapy.
– ACEIs or ARBs are not recommended as monotherapy in black patients in absence of compelling indications [66–68].
Compelling Indications
The choice of drug therapy will be individualized depending upon the patient risk proﬁle, presence of TOD, associated disease
or other comorbid conditions.
– Coronary artery disease
 Angina: BB ± CCB± RAS blockade
 MI or after CABG: BB ± ACEIs or ARBs
– Heart failure: D+ BB+ RAS blockade ± spironolactone
– AF: BB, NDHP CCB, RAS blockade
– Cerebrovascular disease: RAS blockade + CCB± D
– Peripheral arterial disease: RAS blockade + CCB
– Diabetes: RAS blockade ± D
– Renal disease: RAS blockade + D± CCB
– Isolated systolic hypertension (ISH): CCB ± D
– LVH: RAS blockade
– Before non-cardiac surgery: BB
– Migraine, tremors, situational anxiety: BB
– Pregnancy: methyldopa, CCB
– Prostatic hypertrophy: a adrenergic blockers (doxazosin).
Recommended drug selection in absence of compelling indications
Escalating and modifying treatment at 4-week intervals according to BP response and patient’s tolerance.
Step I: 1 or 2 or 3 or 4 or 5
1. HCT amiloride e.g. (moduretic) or chlorthalidone (hygroton) or HCT+ spirinolactone (aldactazide) in the smallest
dose e.g. half tablet (HCT: 12.5 mg) or indapamide in all patients particularly elderly, blacks and obese.
2. BB: cardio-selective with long activity e.g. bisoprolol 2.5–5.0 mg specially in young and female hypertensives and
those with rapid and hyperdynamic heart.
3. Amlodipine: 2.5–5.0 mg specially in elderly patients.
4. ACEIs or ARBs.
5. Combine 1 + 2 or 1 + 3 or 2 + 3 or 1 + 4 if BP > 170/105 mmHg.
Step II: Combine 1 + two other groups if inadequate response in step I.
Step III: Increase dose of amlodipine to 10 mg, if used.
Step IV: Increase dose of ACEI or ARB, if used.
Step V: Use the four drug groups.
Step VI: Add loop diuretic preferably long acting e.g. torsemide (5-20 mg).
Step VII: Add spironolactone (12.5–25 mg).
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severe hypertension, aim to achieve target BP at 2–4 weeks through combination therapy.What to do if there is inadequate BP response?
a. Add another agent (different pharmacologic group).
b. Add thiazide if not given initially.
c. Stress salt reduction.
d. Substitute with another agent if the above measures fail.
e. Seek specialist’s opinion.MEASURES TO IMPROVE PATIENT’S COMPLIANCE:
1. Patient Education: Physician should spend few minutes with his/her patient during ofﬁce visit to discuss the following facts:
a. Hypertension is silent; one can not rely on symptoms to diagnose high blood pressure.
b. Treatment of hypertension is lifelong and without interruption.
c. Hypertension is not treated on demand i.e. give drugs when blood pressure is elevated and stop it when blood pressure is
normal.
d. Hypertension requires life-long monitoring. Blood pressure should be measured regularly at 3–6 months intervals, depend-
ing on risk proﬁle and level of blood pressure.
e. Lifestyle modiﬁcation is an important component of the therapeutic regimen.
f. Antihypertensive drugs can produce side effects.
2. Prescribe Affordable Drugs.
3. Regular Follow-up (3–6 months).
4. Keep Care Inexpensive and Simple:
a. Do the least work-up needed.
b. Add one drug at a time and use the least number of pills.
c. Start with a small dose.
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trained to measure blood pressure accurately. Home blood pressure measurement will improve compliance but not recom-
mended if it causes anxiety and patient should be advised not to change his blood pressure medicines without the consultation
of his physician.Table 6 Antihypertensive Drugs
Chemical name Trade names (examples) Daily dose (mg/d) Frequency /d Notes
Diuretics
Thiazides and thiazide-like diuretics
Hydrocholothiazide (HCT) Hydretic, hydrazide 12.5–50 1 Start with a low dose
Clorothalidone Hygroton 12.5–25 1
Indapamide Natrilix, hypotense 1.5–2.5 1
Loop diuretics
Furosemide Lasix 40–240 2–3 Short acting
Torsemide Torseretic, examide 5–100 1 Long acting
Bumetanide Burinex, edemex 0.5–4.0 2–3
Ethacrinic acid Edecrine 25–100 2–3 In pts with
sulfonamide sensitivity
Potassium sparing diuretics
Spironolactone Aldactone, epilactone 12.5–100 1–2
Diuretics combinations
Amiloride(5 mg)+HCT(50 mg) Moduretic, Yostiretic 1
Spironolactone (25 mg)+ HCT
(25 mg)
Aldactazide 1
Spironolactone (50, 100 mg)+
Frusemide (20 mg)
Lasilactone 1
Triamterene (30 mg) + Xipamide
(10 mg)
Epitens 1
Beta adrenergic blockers (BB)
Selective BB
Bisoprolol Concor, Bistol, Bisocard 2.5–20 1–2
Atenolol Tenormin, Ateno, Blokium 25–100 1–2
Metoprolol Betaloc, Betalol, Low-press 25–200 1–2
Non-Selective BB
Propranolol Inderal, indolol 10–240 2–3
Sotalol Sotacor, betacor 80–160 2
Vasodilator BB
Nebivolol Nebilet, Nevilob 5 1
Carvedilol Dilatrend, Carvid, Carvedilol, Dilatrol 12.5-50 2 Alpha and beta blockers
Labetalol Labetalol, Trandate 100-800 2 Alpha and beta blockers
Calcium channel blockers
Dihydropyridines
Amlodipine Norvasc, Alkapress, Amilo, Myodura 2.5–10 1 Long duration
Felodipine Plendil, Felocor 2.5–20 1 Less lower limb edema
Nifedipine Adalat, Epilat, Epilat-retard 30–120 2–3
Adalat LA 30 1
Nicardipine Pelcard SR 30–60 2
Lercanidipine Caredipine 5–20 1
Lacidipine Lacipil 2–4 2
Nimodipine Nimotop 10–30 2
Nondihydropyridine
Diltiazem Altiazem, Tildium, Delaytiazem 120–360 2–3
Verapamil Isoptin, Isoptin related 120–360 2
Table 6 continued
Chemical name Trade names (examples) Daily dose (mg/d) Frequency /d Notes
Angiotensin converting enzyme inhibitors
Captopril Capoten, capotril, farcopril 75–300 2–3
Enalapril Ezapril, renitec 5–40 1–2
Fosinopril Monopril 10–40 1
Lisinopril Zestril, sinopril, mavipril 10–40 1
Perindopril Coversyl 4–16 1
Ramipril Tritace, ramitac 5–20 1
Trandolapril Mavik, gopten 2–8 1
Benazepril Cibacen 5–20 1
Imidapril Tanatril 5–10 1
Angiotensin receptor blockers
Losartan Cozar, Amosar, Kanzar, Losar 50–100 1–2
Valsartan Tareg, Disartan 80–320 1
Irbesartan Aprovel, Kansartan, X-tension 150–300 1
Telmisartan Micardis, Biocardis 40–80 1
Candesartan Atacand, Candesar 8–32 1
Eprosartan Teveten 400–800 1
Olmesartan Erastapex 20-40 1
Sympatholytics-Alpha-adrenoceptor blockers
Methyldopa Aldomed, Kadomet 500–3000 2–3
Prozosin Minipress 5–10 2–3
Doxazosin Cardura 4–16 1–2
Clonidine Catapress 0.1–0.8 2
Table 7 Drug combinations
Chemical name Trade names (examples) Frequency/d
Thiazide and ACEIs
Ramipril (2.5 or 5 mg) + HCT (12.5 or 25 mg) Tritace Comp. 1
Captopril (25 or 50 mg) + HCT (12.5 or 25 mg) Capozide, Farcopril Plus 1–2
Enalapril (10 or 20 mg)+ HCT (12.5 or 25 mg) Ezapril Co, Co-Renitec 1
Lisinopril (10 or 20 mg) + HCT ( 12.5 or 25 mg) Zestoretic, Sinopril-Co 1
Monopril (10 or 20 mg) + HCT (12.5 or 25 mg) Monozide 1
Benazepril (10 or 20 mg) + HCT (12.5 mg) Cibadrex 1
Prindopril (2 or 4 mg) + Indapamide (1.25 or 0.625 mg) Preterax, Biopretrax 1
Thiazide and ARBs
Candesartan (16 or 32 mg) + HCT (12.5 mg) Atacand Plus, Blopress Plus 1
Irbesartan (150 or 300 mg) + HCT (12.5 or 25 mg) Co aprovel, Co aprovel Forte, X-tension Plus 1
Losartan (50 or 100 mg)+ HCT (12.5 or 25 mg) Hyzaar, Fortzaar, Kanzar-H 1
Telmisartan (40 or 80 mg) + HCT (12.5 mg) Micardis Plus
Valsartan (80, 160, 320 mg) + HCT (12.5 or 25 mg) Co-Tareg, Co-Diovan, Disartan Co 1
Olmesartan (20 or 40 mg) + HCT (12.5 or 25 mg) Erastapex plus 1
Thiazide and BBs
Atenolol (50 or 100 mg) + chlorthalidone (25 mg) Blokuim diu, Tenoret, Tenoretic 1
Bisoprolol (5 or 10 mg) + HCT (6.25, 12.5 or 25 mg) Concor 5, 10 plus, Bistol Plus,
Lodoz, Cardivocare
1
CCBs and ACEI
Amlodipine (5 mg) + Benazepril (10 or 20 or 40 mg) Amlo-ACE 1
Amlodipine (5 or 10 mg) + Perindopril (5 or 10 mg) Coveram 1
Veramapil ER (180 or 240 mg) + Trandolapril (1, 2 or 4 mg) Tarka, Tarka SR 1
CCBs and ARBs
Amlodipine (5 or 10 mg)+ Valsartan (160 or 320 mg) Exforge, Blokatens. 1
CCB and BB
Felodipine (5 mg)+ Metoprolol (50 mg) Logimax 1
CCBs+ ARBs+ HCT
Amlodipine (5 or 10 mg) + Valsartan (160 or 320 mg) + HCT (12.5 or 25 mg) Exforge HCT 1
Reserpine Comninations
Reserpine (0.1 mg)+ Clopamide (5 mg)+ Dihydroergocistine (0.5 mg) Brinerdin 1
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IN ASSOCIATION WITH CARDIOVASCULAR, RENAL DISEASE AND DIABETES
HYPERTENSION ASSOCIATED WITH CARDIOVASCULAR DISEASE
 In chronic stable angina, target BP is <140/90 mmHg. B-blockers, calcium channel blockers and ACE-inhibitors are 1st line
drugs. Excessive lowering of diastolic BP (<70 mmHg) should be avoided.
 In acute coronary syndromes associated with hypertension, B-blockers, non-dihydropyridine CCB, and IV nitrate are
recommended.
 In systolic HF, target BP is < 130/80 mmHg. ACE-inhibitors (or ARB), B-blockers, and diuretics including aldosterone antag-
onists are recommended agents. Other agents include: amlodipine, felodipine, and hydralazine.
 Patients with evidence of left ventricular hypertrophy should receive an ACE inhibitor or ARB, complemented if necessary with
a calcium antagonist.
 Treatment of hypertension with signiﬁcant aortic stenosis should be done cautiously.
 Hypertension is a risk factor for atrial ﬁbrillation and it is also a major risk factor for AF-related thromboembolism. Uncon-
trolled hypertension increases the bleeding risk in patients receiving anticoagulant therapy.
CHRONIC STABLE ANGINA
Management
–Target BP: < 140/90 mmHg. Excessive lowering of diastolic BP (<60–70 mmHg) may, however, reduce coronary perfusion
and augment myocardial ischemia [69].
– Agents:
– BB+ CCB are drugs of ﬁrst drugs.
a. BP should be lowered slowly without excessive diastolic BP lowering (<60–70 mmHg) particularly in elderly patients with
isolated systolic hypertension and those with critical coronary artery disease without revascularization.
b. Attention should be given to aggressive control of other vascular disease risk factors. Low dose aspirin and statins are
needed by all patients.
c. All agents – except alpha adrenergic blockers and short acting dihydropyridine CCB may be used.
d. Beta adrenergic blockers are preferred drugs. In patients with a previous myocardial infarction (MI), they also reduce the
incidence of recurrent MI, heart failure, and mortality [70].
e. Long acting calcium channel blockers relieve ischemia, can induce regression of LVH and delay the progression of athero-
sclerotic plaque.
f. ACE-inhibitors are also drugs of choice to reduce atherosclerotic vascular events, heart failure, and mortality in patients
with or without previous MI and whether LV systolic function is normal or impaired [71,72].
g. Angiotensin receptor blockers should be used in patients who do not tolerate ACE inhibitors (e.g., due to cough or angi-
oedema)
ACUTE CORONARY SYNDROMES (ACS)
Management
 The agents of ﬁrst choice are beta adrenergic blockers. They should be started as early as possible and should be titrated up until
the heart rate is 660 bpm.
 Non-dihydropiridine CCB (Verapamil, Diltiazem) may be used in patients with intact LV systolic function who cannot tolerate
beta blockers.
 Acute reduction of BP by intravenous BB or nitroglycerin is indicated in patients with ST-segment elevation MI candidate for
ﬁbrinolysis with marked elevation of BP (>180/110 mmHg).
 If the acute BP rise is suspected to be due to pain or anxiety, opiate analgesic or a benzodiazepine tranquillizer should be admin-
istered. Excessive use of tranquillizers may increase the risk of hypoxia, delirium, and CCU psychosis.
 Patients with acute severe mitral regurgitation (or septal rupture) should receive sodium nitroprusside infusion to reduce
afterload.
 After stabilization, beta blockers should be continued, and an ACE inhibitor should be added (regardless of LVEF) unless there
is clear hypotension.
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
Management
– Target BP: <130/80 mmHg, however this level is still a controversy.
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a. Patients with high BP and reduced LVEF (<40%) should receive an ACE inhibitor and any of the following beta adren-
ergic blocker: Bisoprolol, Carvidelol, or Nebivelol regardless of the presence or absence of congestive symptoms [73] ARB
should be prescribed to patients not tolerating ACE inhibitors.
b. In presence of congestive symptoms or signs, a diuretic should be used with electrolyte monitoring.
- Spironolactone is another choice; however, its use may be associated with serious hyperkalemia.
HEART FAILURE WITH PRESERVED EF (DIASTOLIC HEART FAILURE)
 Hypertension is the most common cause of heart failure with preserved LVEF [30], and control of BP is the most effective
way to prevent and/or treat patients with diastolic heart failure.
Management
 No particular class of antihypertensive drugs has been shown, convincingly, to reduce morbidity and mortality in these patients.
 Patients with evidence of left ventricular hypertrophy (LVH) should receive an ACE inhibitor or ARB [74], complemented if
necessary with a calcium antagonist
 Patients with congestive symptoms are helped with a diuretic.
 Hypertensive patients with hypertrophic cardiomyopathy should be treated with a BB, with or without a non-DHP calcium
antagonist. These patients may suffer severe LV outﬂow obstruction with the use of diuretics or vasodilators.
 Patients with rapid heart rate >80 bpm usually beneﬁt from rate reduction to improve LV ﬁling. A beta adrenergic blocker or a
non-DHP calcium antagonist may be used in this situation to control both BP and heart rate.
AORTIC VALVE DISEASES
1. Aortic Stenosis:
– Treatment of hypertension should be done cautiously using BB, small dose diuretics; or centrally acting agents. ACE-I
can be used cautiously. Avoid direct vasodilators due the possible hypotensive effect of peripheral vasodilation with ﬁxed
valve obstruction.
– Antihypertensive medications should be started at very low doses and slowly titrated to a therapeutic level.
2. Aortic Incompetence:
– This is the commonest aortic valve lesion with hypertension. Severe lesion is associated with high systolic and low dia-
stolic BP.
– For severe AR, ACE-inhibitors or niﬁdipine are recommended for a diastolic pressure over 90 mmHg, which would be
rare in severe AR.
– These patients poorly tolerate beta adrenergic blockers, since bradycardia increases the regurgitant fraction and reduces
forward cardiac output.
– Hypertension and AR in the context of acute chest pain should raise the possibility of aortic dissection.
– Aortic valve replacement may be followed by acute hypertension.ATRIAL FIBRILLATION (AF)
 Hypertension is a common risk factor for AF (preceded only by advancing age) [75].
 Antihypertensive treatment may contribute to reduce the risk of AF, and it seems ACE-inhibitors and ARBs are superior to
others in the prevention of new-onset AF [76–78].
 Patients with atrial ﬁbrillation treated by a rate control policy (i.e. slowing the ventricular response), should receive either
beta adrenergic blockers or long acting non-DHP calcium antagonists (to control both BP and ventricular rate) [79].
 Patients with AF treated by a rhythm control policy (i.e restoration of normal sinus rhythm), may derive special beneﬁt from
ACE inhibitors or ARBs This is supported by some, but not all, studies addressing this issue.
AORTIC ANEURYSM
 Uncontrolled hypertension is a risk factor for the development and rupture of aortic aneurysm.
 The antihypertensive drugs of choice are beta adrenergic blockers. They should be titrated to a dose enough to reduce the
heart rate to <60 bpm. If further BP reduction is needed, an ACE inhibitor should be used, and then a diuretic may be
added. Target blood pressure is possible < 130/80 mmHg.
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Management
a. Target Blood pressure is possibly < 130/80 mmHg.
b. The drugs of choice are ACE inhibitors [80] and long acting DHP calcium antagonists.
c. In presence of coronary artery disease, beta adrenergic blockers can be used in patients with claudication or asymptomatic
PAD, but not in patients with rest pain or tissue loss [81,82]. The use of combined alpha and beta blockers (Labetalol, Car-
vedilol) may be safer [83].
d. Investigations for resistant hypertension in these patients should include screening for renal artery stenosis.
e. Aggressive lifestyle intervention including walking, cessation of smoking, and lipid lowering with a statin is needed.
POSTURAL HYPOTENSION
 Postural hypotension (see chapter 1) should be suspected in elderly and diabetic hypertensives, and in those who develop
dizziness or fatigue on antihypertensive therapy.
 In these patients it is better to discontinue or reduce the diuretic dose, reduce the dose of ACE inhibitors, avoid alpha
adrenergic blockers. Beta adrenergic blockers and centrally acting agents may be used. Some patients beneﬁt from the
use of graded compression elastic stockings.
 Postural hypotension may be associated with severe supine hypertension. These patients are difﬁcult to manage and should
therefore be referred to a hypertension specialist.
HYPERTENSION ASSOCIATED WITH RENAL DISEASES:
 Measurements of proteinuria at 6–12 months.
 Aim at reduction of micro-albuminuria by >30% within 6 months of starting treatment [84–87].
 Na restriction to 2–3 g/d will reduce urinary protein excretion.
 Need for lower BP in patients with >1 g protein excretion/d (<130/80 mmHg) and use of RASB [88].
 In absence of albuminuria BP target is <140/90 mmHg [89,90].
 Choice of diuretic should be guided by GFR, if 40 ml/min/1.73 m2 use a loop diuretic [30].
 Patients with renal insufﬁciency should be encouraged to reduce dietary salt and protein intake [91,92].
 Target blood pressure is less than 140/90 mmHg. If patients have urinary protein of 1 g/day or greater, the target blood
pressure should be, if tolerable, less than 130/80 mmHg [93,94].
 ACE-I, Angiotensin receptor blockers and loop diuretics are the drugs of ﬁrst choice for hypertensive patients with renal
failure. Dose adjustment is required and when serum creatinine exceeds 3.0 mg/dl, ACE-inhibitors should be used carefully
[95].
 Serum creatinine level often rises during the early phase of treatment with ACE-I or ARBs specially in patients with renal
disease [57,59].
 Calcium antagonists are useful and safe, especially in patients with severe renal dysfunction (serum creatinine >3.0 mg/dl)
[96].
 Thiazide diuretics are ineffective in patients with serum creatinine greater than 3.0 mg/dl [30].
 In patients with severe renal failure (serum creatinine >3 mg/dl) intravenous frusemide 160 mg/day (or its equivalents,
bumetanide or torsemide) or oral frusemide 320–400 mg may be required to control blood pressure when intravascular vol-
ume is expanded.
General Considerations
 Renal insufﬁciency is deﬁned as serum creatinine greater than 1.5 mg/dl in men and greater than 1.4 mg/dl in women. Ele-
vation of serum creatinine may not occur until the glomerular ﬁltration rate has fallen to less than 30% of normal; it is
therefore of limited value in estimating the extent of renal damage [97].
 Hypertension is the single most important factor in the progression of early renal disease [97].
 Hypertension in chronic renal insufﬁciency is secondary to salt and water retention caused by the decrease in renal excret-
ing function. Other mechanisms include activation of the renin–angiotensin system, increased adrenergic activity, and loss
of renal vasodilators.
 Erythropoietin therapy of anemic patients with chronic renal insufﬁciency may cause hypertension or exaggerate pre-exist-
ing hypertension.
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Special Considerations
 Proper control of blood pressure is mandatory. Control of other risk factors (e.g., diabetes, hyperlipidemia) is also essential
for cardiovascular protection.
 The concept of intraglomerular pressure is important, particularly in grossly proteinuric cases. Drugs that reduce the intra-
glomerular pressure are preferred (RAS blockers).
 There is a tendency to develop hyperkalemia with some antihypertensive agents.
 Uremic patients may suffer from autonomic neuropathy. They are susceptible to orthostatic hypotension.
 Uremic patients are already receiving many other medications and drug interactions should be considered.
 Associated medical problems (e.g., diabetes, heart failure, liver disease, hyperlipidemia and hyperuricemia) are commonly
found in these patients.
Target Blood Pressure
 To lower blood pressure to less than 140/90 mmHg and preferably to less than 130/80 mmHg in patients withP1 g/day of
proteinuria [87].
Non Pharmacological Therapy
 Salt should be restricted. Protein intake should be limited according to body weight (0.8 g/kg/day) [91].
 Mild exercise as walking should be encouraged.
 Weight loss in obese patient should be encouraged.
 Smoking should be stopped; it is recognized as an aggravating factor for renal disease progression.
Pharmacological Therapy
 ACE-inhibitors and angiotensin II receptor blockers are the drugs of ﬁrst choice particularly in proteinuric cases [87]. Cal-
cium channel blockers, diuretics, beta blockers and alpha blockers are additive drugs.
 Low-sodium intake and dietary protein restriction enhance the anti-proteinuric effect of ACE-inhibitors.
 ACE-inhibitors are not contraindicated at any level of renal dysfunction, although they should be used cautiously when
serum creatinine values exceed 3 mg/dl.
 ACE-inhibitors excretion is decreased in end stage renal disease, and a lower dose should be given, except for fosinopril.
ARBs need minimal dose regulation unless serum potassium rises.Table 8 Causes of exaggerated or progressive decline in renal function associated with ACE-inhibitors or angiotensin receptor
blockers use.
 Bilateral renal artery stenosis
 Renal artery stenosis to a single functioning kidney
 Polycystic kidney disease.
 Absolute reduction in intravascular volume (gastroenteritis aggressive diuresis)
 Reduction in effective arterial volume (moderate to severe CHF)
 Use of NSAIDs or calcineurine inhibitors e.g. cyclosporine (increased renal vasoconstriction)Angiotensin Receptor Blockers
 Have similar effects as ACE-inhibitors. Losartan and irbesartan in particular, proved to be renoprotective in diabetic
nephropathy patients [98,99].
Diuretics
 Thiazide diuretics are effective as long as the serum creatinine is <2 mg/dl.
 In patients with serum creatinine >3 mg/dl, intravenous frusemide 160 mg/day (or its equivalents; bumetanide or torsemi-
de) or oral frusemide 300–400 mg may be required to control blood pressure when intravascular volume is expanded.
 Potassium retaining diuretics are used in early renal failure only, and with great caution particularly if ACE-inhibitors are
concomitantly administered.
 With aggressive diuretics, potentially reversible worsening of renal function may occur, therefore, close observation is man-
datory with monitoring of body weight, orthostatic blood pressure, renal function and electrolytes.
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 Non dihydropyridine agents are renoprotective because they reduce proteinuria.
 Studies have shown superiority of ACEi combined with dihydropyridine CCBs compared to ACEi and diuretics [100,101].
Beta Blockers
 Adjust doses of drugs excreted through renal route (e.g., atenolol).
 Combined alpha and beta blockers (eg Carvidilol) are preferred.
Antihypertensive Therapy in Hemodialysis Patients
 Hypervolemia plays a major role in the pathogenesis of hypertension in these cases. Proper adjustment of the dry weight is
the ﬁrst line of therapy in controlling hypertension in these patients [102].
 Excessive lowering of blood pressure may increase the mortality in hemodialysis patients. The target blood pressure is 140/
90 mmHg, however other guidelines give no information for target BP lowering and reduction of mortality occurs only in
patients with heart failure and that target BP could not be provided.
 Salt restriction should always be observed.Diabetes and hypertension
Diagnosis
 Diagnostic criteria for diabetes:
FBS 126 mg/dl and/or 200 mg/dl after oral glucose load; random blood sugarP 200 mg/dl with symptoms suggestive of
diabetes (e.g. polyurea) or HbA1C > 6.5 mg % [41].
 Prediabetes
 The levels of fasting glucose range between 100 and 125.9 mg/dl or plasma glucose 2 h after an oral glucose load (75 gm)
is between 140 and 199.9 mg/dl.
 The diagnostic cutoff for the diagnosis of hypertension is lower in people with diabetes (140/90 mmHg) than those without
diabetes or low risk patients (150/95 mmHg).
 Prevalence of hypertension is 1.5-fold higher in diabetic patients relative to non-diabetic patients.Treatment:
 Treatment BP goal: <140/90–80 mmHg and <130/80 mmHg in presence of proteinuria (>1 g/24 h) [28–30]. Other Guidelines
stated that it’s mandatory to reduce SBP if it is >160 mmHg and that it is strongly recommended when it is >140 mmHg. DBP
<85 and reduction of BP <130/80. However, lowering BP <130/80 was not supported by RCTs.
 Reduction of Na intake to <1500 mg/d (<4 g NaCl) is recommended.
 The management of diabetes and hypertension in patients with nephropathy mandates strict glucose and BP control [103].
 The target of HbA1C should be <6.5–7%, this can delay progression from microalbuminuria to macroalbuminuria [104].
 ACEIs and ARBs are superior to other agents in reducing cardiovascular events and deterioration of renal function [98].
 More than one antihypertensive drug is usually needed to control blood pressure [87,105].
 One antihypertensive medication to be given at bedtime.
 Dietary protein reduction in patients with diabetic nephropathy (0.6 g/kg/d).HYPERTENSION IN SPECIAL GROUPS
OBSTRUCTIVE SLEEP APNEA (OSA)
 OSA is considered one of the potentially reversible secondary causes of hypertension and among the causes of resistant hyper-
tension [106].
 OSA is characterized by recurrent episodes of cessation of respiratory air?ow caused by upper airway inspiratory collapse dur-
ing sleep, with a consequent decrease in oxygen saturation.
 Hypertension affects approximately 50% of patients with OSA [107].
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 Clinician should always ask for symptoms of obstructive sleep apnea especially in patient with resistant hypertension.
Symptoms include choking episodes and interruption of breathing during sleep, nocturnal snoring reported by the bed
partner, daytime somnolence, with impaired concentration.
 Large neck circumference with facial pufﬁness [108].
Treatment
 Weight loss in obese subjects ameliorates the syndrome [109].
 Treatment with continuous positive airway pressure (CPAP) devices is the most effective treatment for OSA. CPAP ther-
apy reduces the systolic blood pressure by 2.5 mmHg and diastolic blood pressure by 1.8 mmHg [110].
 In addition to weight control and CPAP, spironolactone may be particularly effective in controlling blood pressure because
of secondary hyperaldosteronism in patients with OSA [111].
OBESITY
 Overweight is deﬁned as a body mass index (BMI)P 25 kg/m2. BMI is body weight in kilograms divided by the height in
meters squared. Obesity is deﬁned as a BMI P30 kg/m2; morbid obesity is a BMI >40 kg/m2.
 Obesity and weight gain have been identiﬁed as one of the most important determinants of hypertension.
 False high blood pressure readings in obese patients may result from the use of inappropriate cuff (small) size.
 Central or visceral obesity leads to a substantial increase in cardiovascular disease (CVD) morbidity and mortality. It is
assessed through measuring waist circumference.
 Upper limit for a normal waist circumference for Egyptian men <93.5 cm and <92.5 cm for women [42].
Management of Obesity
 Attempt weight loss treatment for all patients with BMI P30 kg/m2 and for patients with a BMI between 25 and 29.9 or
have a high waist circumference, and 2 or more risk factors [112].
 Therapy begins with lifestyle changes in diet and physical activity.
 An initial weight loss of 10% of body weight, achieved over 6 months is a recommended target and results in a decrease in
blood pressure by 5–20 mmHg [113].
 After ﬁrst six months of weight loss therapy, the priority should be weight maintenance, which is achieved through the
combined changes in diet, physical activity and behavior.
 Weight-reduction through bariatric surgery in the morbidly obese with signiﬁcant co-morbidities can result in improved
metabolic parameters and blood pressure [114].
Management of Hypertension in Obese Patients
Pharmacologic Treatment
 Non-pharmacological treatment is usually insufﬁcient and pharmacological treatment must be added to control BP in
obese hypertensive patients.
 Low-dose thiazide diuretic is a good choice since they counter volume expansion and reduce BP effectively in obese
patients.
 Modern b-blockers such as nebivelol and carvedilol, (vasodilator BBs), and bisoprolol; a highly selective beta blocker, have
less adverse effects than the older ones.
 In patients with dysglycemia and/or dyslipidemia, drugs such as ACEIs, ARBs and calcium channel blockers might con-
stitute the best choice
RESISTANT HYPERTENSION
 Resistant hypertension is deﬁned as persistent elevation of blood pressure above 140/90–150/95 mmHg in patients who are
adhering to triple-drug regimen including a diuretic, and all three drugs are prescribed in maximum recommended and tol-
erated doses for at least three months [115].
 For older patients with isolated systolic hypertension, resistance is deﬁned as failure of an adequate triple-drug regimen to
reduce systolic blood pressure below 160 mmHg [116].
 The diagnosis of resistant hypertension requires accurate blood pressure measurement to conﬁrm persistently elevated
blood pressure levels.
 Referral to a specialist should be considered.
 Although an inadequate response to antihypertensive therapy is unfortunately common, true resistant hypertension is not
common in general practice.
Table 9 Substances that Can Elevate Blood pressure [120].
NSAIDs (nonsteroidal anti inﬂammatory drugs)
Oral contraceptives
Glucocorticoids
Mineralocorticoids
Sympathomimetics (e.g., nasal decongestants, appetite suppressants)
Licorice
Phenothiazines
Antidepressants
Cyclosporine
MAO inhibitors and tyramine rich foods
Erythropoietin
Cocaine
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 False high blood pressure.
 True high blood pressure.
 True resistant hypertension
False High Blood Pressure
 Cuff hypertension: due to the use of inappropriate (small) cuff size
 Ofﬁce (white coat) hypertension: 15–30% of patients diagnosed with hypertension actually have normal blood pressure at
home or on ABPM.
 Pseudo-hypertension: Seen in elderly patients with atherosclerotic arteries, and calciﬁed brachial artery. The cuff pressure is
inappropriately high compared with intra-arterial pressure.
True High Blood Pressure
 Inappropriate Drug Therapy
A suboptimal medical regimen is the commonest cause of resistant hypertension [117].
– Incorrect drug combination: e.g., using drugs from the same pharmacologic group.
– Inadequate dosing: e.g., small dose, short acting preparation given once daily. Poor compliance with treatment and lifestyle modiﬁcation
– Poor adherence to the prescribed medical regimen is possibly the most common etiology of resistant hypertension [118].
One-half of all patients discontinue antihypertensive medications within one year or receive irregular treatment [119].
– Lifestyle: high salt intake, alcohol excess, uncontrolled obesity, continuous stressful exposures.
 Ingestion of substances that can elevate blood pressure (Table 9)
 Obstructive sleep apnea.
True Resistant Hypertension
 Extracellular volume expansion [121]
– Inadequate diuretic therapy.
– Renal insufﬁciency.
– Therapy with direct arterial vasodilators.
– Excessive sodium intake.
 Secondary Hypertension
Management
 Blood pressure should be measured accurately according to guidelines. False-high blood pressure readings should be
excluded. Vasopressor medications, and drug therapy needs to be reviewed for appropriateness of drug dose and combi-
nation. Salt restriction, weight reduction and stress management are essential.
 Rule out white-coat hypertension by measurement of blood pressure at home or by ambulatory monitoring.
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 Persistent volume expansion (even without edema) contributes to resistant hypertension. Effective diuretic (loop diuretic)
use is almost always necessary to achieve blood pressure control [121].
 Spironolactone in a low dose usually 25 mg daily provides signiﬁcant additional blood pressure reduction when added to
multidrug treatment regimens [122].
 If these measures fail, consider taking the opinion of a specialist or hospitalization.
 Renal denervation by catheter-based radiofrequency ablation of the renal sympathetic nerves lowers though of the blood
pressure in patients with resistant hypertension, it is still under investigation. Long-term data regarding efﬁcacy and safety
of radiofrequency ablation remain limited [123–125].
Resistant Hypertension
Source: M. Mohsen Ibrahim, 2013
HYPERTENSION IN THE ELDERLY
 BP goal in the elderly is <150/95 mmHg
 Reduction in cardiovascular morbidity and mortality can be achieved with antihypertensive treatment in patients older than
above 80 years.
 Low-dose thiazide diuretics and long acting dihydropridine calcium antagonists constitute the ﬁrst line drug treatment in elderly
patients.
 The diagnostic pitfalls of psuedohypertension, auscultatory gap and white coat hypertension should be carefully considered in
these patients.
 Because of the increased risk of postural hypotension in the elderly, BP should always be measured also in standing posture.
Management of Elderly Hypertensive
 Start with smaller antihypertensive doses, at almost half the standard doses and increase the dose gradually over several
weeks.
 Check blood pressure always in supine and standing positions. Titrate doses according to standing pressures to avoid exces-
sive orthostatic hypotension.
 Check for adverse drug reactions which are two to three times more common in the elderly.
 Follow-up visits should be scheduled every 2–4 weeks until blood pressure is controlled.
 Consider co-morbid conditions and poly-pharmacy which are common in the elderly.
 Avoid centrally acting agents that may cause drowsiness, depression or impaired cognitive function
 Avoid drugs which exacerbate hypertension e.g. nonsteroidal anti-inﬂammatory drugs
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 The elderly (especially women) have increased sensitivity to salt [126]. Blood pressure is readily increased by salt loading, and
reduced by salt restriction.
 Limit salt intake to less than 3–4 g NaCl/day [127,128].
Drug Therapy
 Trials speciﬁcally addressing treatment of isolated systolic hypertension have shown the beneﬁt of thiazides and long acting
calcium antagonists as the drugs of choice [129].
Octogenarians (over 80 years)
 Successful treatment of hypertension in octogenarians was shown to reduce CV risk and mortality based on recently available
data [130].
 Those with SBP more than 160 mmHg are candidates for antihypertensive drugs [130].
 Lowering of SBP less than 130 and DBP less than 65 mmHg should be avoided [130].
Isolated Systolic Hypertension
 Systolic blood pressure greater than 160 mmHg with diastolic blood pressure less than 90 mmHg.
 Systolic blood pressure is a strong predictor of cardiovascular complications than diastolic blood pressure [131,132].
 Lowering of systolic blood pressure in the elderly is associated with signiﬁcant reduction in cardiovascular mortality, stroke,
heart failure, myocardial infarction, and dementia [133].
 CCB, diuretics and ARBs are the drugs of choice [133].HYPERTENSIVE EMERGENCIES
 Hypertensive crisis is arbitrarily deﬁned as severe elevation of blood pressure (exceeding 220 mmHg systolic and/or 120 mmHg
diastolic). It is considered an emergency when complicated by acute progressive target organ damage such as encephalopathy ,
cerebral hemorrhage, pulmonary edema etc. . .
 Patients who present with severe elevation of blood pressure in the absence of acute target organ damage have hypertensive
urgency. They can be managed as out-patients using a combination of rapidly acting oral antihypertensive drugs.
 Patients who present with a hypertensive emergency should be hospitalized for rapid controlled lowering of blood pressure in
the ICU. The target blood pressure level and the rate of reduction depend on the nature of emergency, the age of the patient and
the clinical response.
 The parenteral antihypertensive drugs of choice (sodium nitroprusside, nitroglycerin and labetalol) are rapidly acting parentral
agents with a short duration of action which effectively reduce the systemic vascular resistance. Their action can be rapidly
reversed in case of an adverse clinical response.
General Principles
 Avoid using rapidly acting sublingual nifedipine and captopril that may result in uncontrolled reduction of arterial pressure and
marked organ hypoperfusion leading to catastrophic end-organ damage such as cerebral infarction, or acute myocardial infarc-
tion [134,135].
 Intravenous diuretics should not be used as initial therapy in a hypertensive crisis unless the patient presents in acute pulmonary
oedema or there is evidence of extracellular volume expansion [135].
 Avoid rapid and uncontrolled reduction in blood pressure to the normal level within the ﬁrst few hours, that may lead to target
organs hypoperfusion. The mean arterial pressure should be reduced to a level of 120 mmHg (160/100) over several hourss
[135]. In patients with acute pulmonary edema or aortic dissection, rapid lowering of BP (within <1 h) may be needed.
 Most patients with severe hypertension (DBPP110 mmHg) have no acute end-organ damage. Rapid antihypertensive therapy
may be associated with signiﬁcant morbidity.
 In patients with hypertensive urgencies, BP is lowered gradually over a period of 24–48 h with oral medication [135].
 The immediate goal of IV therapy is to reduce the DBP by 10–15% or to less than 110 mmHg [135].
 All patients with a hypertensive emergency should be managed in an intensive care unit, where the patient can be closely mon-
itored. Intra-arterial blood pressure monitoring may be required in patients with blood pressure that is labile and difﬁcult to
control.
Table 10 Types and Clinical Presentation of Hypertensive Emergencies [136]
 Malignant hypertension with papilloedema
 Cerebrovascular
- Hypertensive encephalopathy
- Atherothrombotic brain infarction with severe hypertension
- Intracerbral haemorrhage
- Subarachnoid haemorrhage
 Cardiac
- Acute aortic dissection
- Acute left ventricular failure
- Acute myocardial infarction
 Renal
- Acute glomerulonephritis
- Renal crisis from collagen vascular disease
- Severe hypertension after kidney transplantation
 Excessive circulating catecholamines
- Pheochromocytoma crisis
- Food or drug interactions with monoamine-oxidase inhibitors
- Sympthomimetic drug use (cocaine)
- Rebound hypertension after sudden cessation of antihypertensive drugs e.g. clonidine.
 Eclampsia
 Surgical
- Severe hypertension in patients requiring immediate surgery
- Postoperative hypertension
- Postoperative bleeding from vascular suture lines
- Severe body burns
Table 11 Diagnosis of Hypertensive Emergencies [137].
Diagnostic category Diagnosis
Acute aortic dissection Abnormal CTangiogram or transesophageal echocardiogram of the aorta
Acute pulmonary edema Interstitial edema on chest radiograph
Acute coronary syndromes/
acute MI Clinical diagnosis, and/or changes on electrocardiogram, and/or elevations of cardiac
biomarkers
Acute renal failure Elevated serum creatinine, proteinuria
Severe Pre-eclampsia, eclampsia Proteinuria; hemolysis, elevated liver enzymes, low platelets; seizures, HELLP syndrome
Hypertensive encephalopathy Clinical diagnosis including altered mental status associated with elevated blood
pressure – may see papilledema, arteriolar hemorrhage or exudates on fundus exam;
may note cerebral edema with a predilection for the posterior white matter of the brain
on MRI after clinical diagnosis
Subarachnoid hemorrhage Abnormal CT of the brain; red blood cells on lumbar puncture
Intracranial hemorrhage Abnormal CT of the brain
Acute ischemic stroke Clinical diagnosis including new neurological deﬁcit, excluding other causes
Acute post operative hypertension Clinical diagnosis including onset within 2 h of surgery, lasting 6 h or less
Sympathetic crisis* Clinical diagnosis in the setting of sympathomimetic drugs including cocaine,
amphetamine, positive urine drug screen, or pheochromocytoma demonstrated by 24 h
urine for catecholamines and metanephrine
Abbreviations: CT = computed tomography, HELLP= hemolysis, elevated liver enzymes, low platelets, MRI = magnetic resonance imaging.
* In this syndrome, acute end organ dysfunction may not be measurable, but complications affecting the brain, heart, or kidneys may occur in
the absence of acute treatment.
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Table 12 Causes of secondary hypertension.
Renal causes:
– Chronic renal parenchymal disease (3–5%)
– Renal artery stenosis (1–2%)
Drugs
Endocrinal causes
– Primary hyperaldosteronism (5–12%)
– Hyper- or hypothyroidism
– Pheochromocytoma (<0.3%)
– Cushing syndrome
Aortic Coarctation
Other Causes
– Central nervous system diseases e.g., brain tumor
– Sleep apnea, acute porphyria, polycythemia vera
Primary Aldosteronism
(see Algorithm 7)
 Most common form of secondary hypertension [146]
 Persistent elevations of aldosterone can result in end-organ damage [147]
 Prevalence among hypertensive patients [148,149]
1. Unselected hypertensive patients: 4–5.9%
2. Resistant hypertension: 11.3%
 Subtype differentiation
1. Bilateral-adrenal hyperplasia 70% 2. Adenoma 30%
 Suspicion of primary aldosteronism [150]
1. Spontaneous or unprovoked hypokalemia with renal K wasting
2. Severe diuretic-induced hypokalemia (63 mE/L) that does not normalize after discontinuation of diuretics [151]
3. Hypertension with adrenal adenoma.
4. Resistant hypertension with no other evidence of secondary cause
5. Family history of primary aldosteronism
 Laboratory tests
1. Hypokalemia: serum K< 3.5 mEg/L with 24 h urinary KP 30 mEq [152]
2. Hypokalemia 63.5 mEg/L provoked by a high salt intake
3. Ratio of plasma aldosterone concentration (PA) to plasma renin activity (PRA) (PA: PRA) is the
best screening test for primary aldosteronism [152,153].
4. Combination of PA:PRA ratio >30 and PA >20 mg/dl had sensitivity of 90% and speciﬁcally of 91% [154]
 Drugs affecting plasma renin and aldosterone levels [155]
1. BB ﬁ ﬂ plasma renin ﬁ ﬂ PA
2. ACE and ARBs ﬁ›renin, ﬂPA
 Adrenal CT scan: high-resolution CT with contrast. Adenomas are <3.0 cm, well circumscribed
and homogenous, X-ray attenuation of 610 Hounsﬁeld units (HUS) [156].
Treatment
 Laprascopic adrenalectomy in conﬁrmed unilateral adenoma [150].
 Spironolactone in adrenal hyperplasia.
Pheochromocytoma
Prevalence
 0.3% of patients with hypertension [157]
Suspicion
 Family history of pheochromocytoma
 History of non-cardiogenic pulmonary edema
 Hypertension crisis with glucocorticoid or ACTH administration [158]
 Episodes suggestive of acute myocardial infarction with normal coronary angiography [159]
 Lactic acidosis in absence of shock
 Hypertension crisis during surgery
Clinical Characteristics
 Triad of episodic headaches, sweating, tachycardia
 Patient may be completely asymptomatic and have elevated circulating catecholamines [160]
Biochemical Testing [161]
 Plasma:
1. Catecholamines > 2000 pg/ml
2. Free metanephrine (MN) >1.21 nmol/l
3. Free non-metanephrine (NMN) >2.21 nmol/l
 Urinary metanephrines > 1.8 mg/24 h
 If biochemical tests are in the indetermination range: use clonidine suppression test, does not suppress catecholamine release by supra-
renal tumor. It acts at adrenergic nerve endings
High Negative Predictive Value (exclude pheochromocytoma) if [161]
1. Plasma free MN <0.5 nmol/L, NMN <0.9 nmol/l
2. Plasma catechlamines <1000 pg/ml
3. Urinary metanephrine <1.3 mg/ 24 h
Adrenal CT Scan
 Dense, vascular and heterogonous appearance with HUS P 22.
Treatment
 Surgical removal after preoperative preparation
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118 MM. Ibrahim The most common clinical presentations of hypertensive emergencies are [135] cerebral infarction (24.5%), pulmonary edema
(22.5%), hypertensive encephalopathy (16.3%), and congestive heart failure (12%). Other clinical presentations associated with
hypertensive emergencies include intracranial hemorrhage, aortic dissection, and eclampsia, as well as acute myocardial infarc-
tion (see Tables 10 and 11).
Management of Hypertensive Emergencies
 The primary goal of the emergency physician is to determine which acute hypertensive patients are exhibiting symptoms of end-
organ damage and require immediate intravenous (IV) parenteral therapy. In contrast, patients presenting with acutely elevated
BP (systolic BP [SBP] >200 mmHg or diastolic BP [DBP] >120 mmHg) without symptoms and whose BP stays signiﬁcantly
elevated to this level on discharge, should have initiation of medical therapy and close follow-up in the outpatient setting.
 The goal of therapy is to reduce the mean arterial pressure in a calculated and controlled manner using potent rapidly acting
antihypertensive agents with a short duration of action.
 Rapid controlled blood pressure lowering is recommended in cerebral infarction if blood pressure is 220/120 mmHg or greater
(180/105 mmHg in patients with cerebral hemorrhage). Do not lower mean blood pressure by more than 25% in the ﬁrst two
hours, then to 160/100 mmHg within the next six hours [135].
 Rapid reduction of blood pressure to normal levels (<140/90 mmHg) is indicated in patients with aortic dissection, acute pul-
monary oedema, and in selected patients with cerebral hemorrhage (ICH).
 BP targets currently used for tissue plasominogen activator (<180/110 mmHg) in patients with ischemic stroke could be ben-
eﬁcially extended to all patients within the ﬁrst 24 h avoiding sharp BP reductions [135].
 Achieving SBP 130–140 mmHg over the initial 24 h in ICH was beneﬁcial in the recent INTERACT study [138].
 For acute ischemic stroke, the preferred medications are labetolol and nicardipine. If the patient is not a candidate for throm-
bolytic therapy, withhold antihypertensive medications unless SBP is >220 mmHg or DBP >120 mmHg [139].
 For acute intracerebral hemorrhage, the preferred medications are labetalol, nicardipine and esmolol. Avoide nitroprusside and
hydralazine [139].
 If there are signs of increased intracranial pressure (ICP), maintain SBP < 180 mmHg for the ﬁrst 24 h after onset. In patients
without increased ICP, maintain SBP < 160 mmHg for the ﬁrst 24 h after symptoms onset [139].
Antihypertensive Drug Therapy
Sodium Nitroprusside
 This is the drug of choice in most hypertensive emergencies. It is a potent direct vasodilator which acts as a nitric oxide donor to
reduce both the preload and the afterload.
 It should be administered (IV infusion) in the ICU under close monitoring of arterial blood pressure, preferably through an
arterial line. The dose ranges from 0.25 to 10 lg/kg/min. The infusion is started at 15 lg/min and cautiously increased by 5–
10 lg/min every 3–5 min until the desired blood pressure is reached [140].
 It should be avoided whenever possible in patients with hepatic or renal failure.
Nitroglycerin
 This widely available direct vasodilator acts primarily by reduction of venous preload. However at high infusion rates, it also
reduces the systemic vascular resistance.
 The dose ranges from 20–150 lg/min. Because of its favorable effect on myocardial ischemia, it is particularly effective in acute
coronary syndromes and acute pulmonary oedema. The initial dose is 5 lg/min increased in increments of maximum rate of
200 lg/min.
Labetalol
 Beta and alpha adrenergic receptor blocker given as 50 mg bolus to be repeated every 5 min to a maximum of 200 mg, then
intravenous infusion of 2 mg/min. The hypotension effect begins within 2–5 min after an IV dose and persists for about 2–
4 h [140].
Clonidine
 Oral clonidine (0.1 mg every 20 min) used for the treatment of hypertensive urgencies. The onset of action is within 30 min–2 h,
with duration of action of 6–8 h.
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 The use of estrogen-containing oral contraceptive (OC) pills can cause secondary hypertension in young women.
 Newer progestins such as drospirenone contain a spironolactone-like moiety [141] with mild mineralocorticoid antagonist
action; as a result, drospirenone-estrogen combinations generally cause a small decrease in BP.
 Mild preeclampsia is managed by close observation of the mother and fetus preferably in hospital. If the diastolic blood pres-
sure remains persistently >100 mmHg, oral antihypertensive drug therapy is instituted.
 Severe preeclampsia (SBP > 169 mmHg and/or DBP > 109 mmHg) is a medical emergency chieﬂy because of the high risk of
maternal death and intracerebral hemorrhage. The mother should be hospitalized for rapid lowering of the blood pressure using
IV antihypertensive drugs , anticonvulsant therapy, and timely induction of labor after stabilization of the blood pressure.
 The oral antihypertensive drug of choice in pregnancy is methyldopa [142]. Alternatives include CCB and labetalol.
 All antihypertensive drugs which are excreted in breast milk are present in very low concentrations except atenolol and nifed-
ipine which attain high levels in breast milk and should be avoided in lactating mothers.
Deﬁnition of Hypertension in Pregnancy
Hypertension in pregnancy is deﬁned as blood pressure exceeding 140/90 mmHg. The diagnosis should be based on at least two
high blood pressure readings on two separate occasions. Korotkoff phase V is now recommended for the measurement of diastolic
blood pressure in pregnancy with phase IV being indicated only if Korotkoff sounds persist at cuff pressures approaching
0 mmHg.
Classiﬁcation of Hypertension in Pregnancy
There are four major hypertensive disorders in pregnancy:
1. Preeclampsia–eclampsia.
2. Chronic preexisting hypertension.
3. Preeclampsia superimposed on chronic hypertension.
4. Gestational hypertension. Chronic Preexisting Hypertension: hypertension that predates pregnancy or a blood pressure >140/90 which develops before
the 20th week of gestation. Rarely high blood pressure is the result of secondary causes as renal parenchymal disease.
 Gestational Hypertension: is transient mild hypertension during the third trimester. It carries little risk to the mother or
fetus. The hypertension typically resolves shortly after delivery, but tends to recur with subsequent pregnancies and
may represent a risk factor for future development of essential hypertension.
 Preeclampsia: hypertension associated with proteinuria which develops after the 20th week of gestation.
 Eclampsia: the development of convulsions unrelated to other cerebral conditions during the course of preeclampsia.
Oedema occurs in up to 60% of normal pregnancies, and is no longer used in the diagnosis of pre-eclampsia.
Pharmacological Management of Hypertension in Pregnancy
Mild Hypertension
 Pregnancy is allowed to mature as long as blood pressure is controlled and other signs of severe preeclampsia are absent.
 Patients with a diastolic pressure of 90–105 mmHg should be put under close observation. A short period of hospitalization
may be required.
 If the diastolic blood pressure remains persistently >100 mmHg, oral antihypertensive therapy can be started. Methyldopa
is the drug of choice. Possible alternatives include labetalol and long acting nifedipine.
 Never use ACEIs or ARBS during pregnancy due to its teratogenic effects.
 Avoid the use of diuretics during pregnancy because of its relatively low efﬁcacy, risk of hypovolemia, stimulation of the
renin-angiotensin system, hyperuricemia, hyponatremia and neonatal thrombocytopenia [143].
Severe Hypertension:
 Patients with systolic blood pressure >169 or diastolic blood pressure >109 mmHg should be hospitalized [143]. Manage-
ment includes rapid lowering of blood pressure, prophylactic anticonvulsant therapy and timely induction of labour.
 In patients with ominous features of preeclampsia, immediate delivery is mandatory.
 IV nitroglycerin, or IV labetalol can be used in severe hypertension. IV hydralazine is no longer the parentral drug of choice
because of its perinatal adverse effects
 IV magnesium sulfate is the drug of choice for preventing eclamptic convulsions. It is administrated slowly as a loading
dose of 6 g diluted in 150 ml glucose 5% administered over 20–30 min followed by continuous infusion of 2 g/h.
Table 13 Summary of Diagnosis and Treatment of Some Forms of Secondary Hypertension.
Cause and frequency Clinical clues Screening test Deﬁnitive test Treatment
Renal parenchymal
hypertension
(3–5%) – History of renal disease
– Abnormal urine sediments
Urinary sediments, pyuria, elevated creatinine – Abdominal ultrasonography
– Radiologic examination
– Renal biopsy
– Drug therapy for hypertension
– Speciﬁc urologic treatment
Renovascular
hypertension (1–2%)
– Onset before 30 or after 50 years
– Abrupt onset
– Resistant hypertension
– Multi-site atherosclerosis
– Abdominal bruit
– Flash pulmonary edema
– Azotemia on ACE-I or ARBs
Captopril renography
– sensitivity 83%
– speciﬁcity 93%
Renal Duplex
– sensitivity 95%
– speciﬁcity 93%
– Renal arteriography
– Digital subtraction angiography
– Spiral CT*
– Angioplasty + stenting
– Drug therapy
– Surgery
Aortic Coarctation
(< 0.5%)
– Delayed/absent femoral pulse
– ﬂarm/leg blood pressure difference
– LVH**
– Precordial systolic ejection murmur
– Systolic/continuous back murmur
– Chest X-ray: rib notching
– ECG: LVH**
– Echocardiography
– Aortography. – Surgical repair.
– Balloon angioplasty.
Primary
aldosteronism (5–
12%)
– Polyuria
– Muscle weakness
– Hypokalemia
– Excess urinary K+ loss
– High plasma and urinary
aldosterone, not suppressible
– Low renin, persistent with
standing or frusemide
– CT* / MRI
– Surgical removal
– Spironolactone ± thiazide
& loop diuretics
Pheochromo-
cytoma (< 0.3%)
– Proxysmal hypertension
– Headache, chest or abdominal pain
– Sweating, palpitations, pallor
– 24h urinary metanephrin & nor-metanephrin
(sensitivity and speciﬁcity >95%)
– CT* / MRI / MIBG scan
– Angiography
– Surgical removal after medical
preparation
The following procedures should be ordered only by senior consultant
 Bariatric Surgery
 CPAP
 Conﬁrmatory test for 2ry HTN
 MIBG: 131  I- Metaiodobenzylguanidine
 MRI: Magnetic Resonance Imaging.
* CT: Computerized Tomography
** LVH: Left Ventricular Hypertrophy
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 The prevalence of hypertension in children and adolescents varies from 1% to 2%.
 The blood pressure measurement in a child should be compared with the childhood reference data tables based on age, gender
and height.
 High blood pressure (hypertension) in children is diagnosed when average systolic blood pressure or diastolic blood pressure (or
both) is equal to or greater than the 95th percentile for age and gender [144].
 Younger children with severe blood pressure elevation more often have secondary hypertension, and need careful clinical eval-
uation. The major causes of secondary hypertension in children and adolescents are of renal parenchymal origin. Cardiovas-
cular and renovascular causes are second in frequency. Aortic coarctation can be easily diagnosed by careful examination of
the lower limb pulsations (delayed and weak femoral compared with radial pulsations).
 Treatment of essential hypertension is still empirical; the ﬁrst step is restriction of excess caloric and sodium intake.
 In hypertensive children and adolescents in whom the blood pressure remains elevated despite life style modiﬁcation, pharma-
cologic therapy is recommended with the initial choice being a diuretic or a beta-blocker in doses adjusted to body weight.
SECONDARY HYPERTENSION
Patients Presenting with any of the Following Clinical Clues, should Suggest a Secondary Cause for Hypertension:
 Onset of hypertension before age 25 or after age 60 years.
 Sudden onset, change from normal blood pressure to severe hypertension in less than a year.
 Resistant hypertension.
 Poor response to prior effective drug therapy.
 Paroxysmal attacks of hypertension with palpitation, pallor, sweating and tremors.
 Multiple system involvement on initial evaluation.
 Delayed and weak femoral pulses with lower blood pressure in the lower extremities.
 Continuous abdominal bruit.
 Renal masses.
 Advanced end organ damage: more than grade 2 retinopathy or serum creatinine >2.0 mg/dl .
 Laboratory abnormalities: (e.g., hypokalemia, or hypercalcemia).
Secondary hypertension refers to high blood pressure from an identiﬁable underlying cause (see Tables 12 and 13). It may occur
in 5–10% of hypertension cases, the most common causes are chronic renal disease, and primary hyperaldosteronism [145].
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Algorithm 1. Diagnosis of hypertension (A)
Algorithm 2. Diagnosis of hypertension (B)
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Antihypertensive drug treatment initiated 
Target BP achieved
Target BP not achieved
at 3 months
Medium — low risk*
• Intensify lifestyle advice
• If partial BP response: add drug from 
another class at low dose
High risk*
• Add second agent from another 
class
• Increase doses to achieve target 
BP
If target still not achieved despite treatment adjustments
• Consider specialist care
• Further investigations as indicated
Medium — low risk*
• Check every 6 months
High risk*
• Check every 3 months
* Absolute cardiovascular risk assessed based upon number of risk factors, TOD, CV and CKD
Algorithm 4. Monitoring of drug therapy
Frequency of Checking BP 
(Interval to Next Visit)
High Risk Low/ intermediate risk
2 W interval
BP at target on 2 
consecuve visits
Absent response
BP not at target
Add another drug
1-2 m interval
Recheck in 3-6 m
Recheck in 1-2 m
BP at target on 2 
consecuve visits
Not at target
Add a 3rd drug
Recheck in 1 m
Recheck in 1 m
124 MM. IbrahimAlgorithm 5. Monitoring and management of rising serum creatinine after initiation of ACE-inhibitors or ARBs.
Initiation of ACE-inhibitors or ARBs.
Serum Creatinine level after 2-4 weeks
% rise in serum 
creatinine relative 
to baseline
<30% 30-50% >50%
Continue ACE-
inhibitor / ARBs Discontinue ACE-inhibitor / ARBs
• Dose by 50 %
•S. Cr after 4 weeks
<30% >30%
Continue ACE-
inhibitor / ARBs
Discontinue ACE-inhibitor / 
ARBs
Exclude
NSAIDs use
Hypovolemia
Excess diuresis
Renal artery 
stenosis
Polycystic kidney
Baseline Scr
Algorithm 6. Diagnosis of renal artery stenosis. (See below-mentioned references for further information.)
Clinical Clues
Onset of hypertension before age 35 year
Severe hypertension after age of 55 year
Malignant or resistant hypertension
Development or worsening of renal dysfunction after administration of ACE-inhibitors or ARBs
Unexplained atrophic kidney or size discrepancy between kidneys > 1.5 cm
Unexplained flash pulmonary edema
Refractory CHF
Refractory angina pectoris Bruits /PAD
Diagnostic tests
Non-invasive studies
Duplex ultrasound, MRA, CT 
angiography
Invasive studies
Abdominal aortography (performed during 
coronary / peripheral angiography)
Evidence of RAS
Evidence of 
RAS
-ve test but still high clinical 
index of suspicion]
Renal catheterization
•Angiography
•Hemodynamic
Evidence of RAS
Egyptian Hypertension Guidelines 125Algorithm 7. Diagnosis of primary hyperaldosteronism
Screening
Confirmation
Localization
Hypertension ± Hypokalemia
Plasma aldosterone and renin level
(morning blood sample while patient is seated)
(avoid diuretics, ß-blockers, ACEIs, ARBs, spironolactone)
PRA <0.5 ng/ml/hr
Aldosterone >15 ng/dl
(Ratio >50 strongly suggestive)
PRA >1.0 ng/ml/hr
Aldosterone <12 ng/dl
(Ratio <20 rules out 1º Aldo)
Plasma aldosterone > 10 ng/dl after 2 L Normal Saline over 
4 hrs or 24-hr urine aldosterone on 4th day of salt loading > 14 µ/d (10-
12 g NaCl p.o. with 24-hr urine Na >200 mmol/d)
Aldosterone
Producing adenoma
Bilateral
hyperplasia
Unilateral mass >1 cm Bilateral enlargement
Procedure
CT or MRI
Therapy Spironolactone, 
eplerenone, or 
Amiloride+ thiazde
Calcium antagonist
Unilateral adrenalectomy
If the above are ambiguous, refer to experience investigators for:
Adrenal venous sampling Lateralize EqualCOMMENTS ON EGYPTIAN GUIDELINES
Egyptian Guidelines Development
Developed by expert panel of 28 members (guidelines working group) which included writing group and advisory board. Six
writing groups: reviewed pertinent literature and 13 recent national and international guidelines. Guidelines content were reviewed
during a number of meetings for approval by working group members. Whenever there was a disagreement, voting was needed for
reaching a consensus. Final draft was sent to 600 practitioners and internists and displayed on internet EHS website. Final
document was prepared taken into consideration feedback and comments from medical community. Final document was ap-
proved by all working group members.
While preparing the guidelines, the following points were considered:
1. Guidelines should be relevant to the way in which health care is delivered.
2. Deﬁne practices that meet the needs of most patients in most situations.
3. Best patient care with least expensive management, limiting laboratory testing to a minimum and prescribing affordable
drugs.
4. Limiting drug therapy to truly hypertensive patients particularly those at high risk.
Process of guidelines development differed. In developing countries such as Malaysia, the process was similar to ours initiated
by the Malaysian Society of Hypertension. A committee of limited number of members including different specialties convened
and guidelines were posted on websites for comments and feedback.
The Indian guidelines [163] were formulated by a core committee supported by a working group and the document was circu-
lated to 250 doctors, whose input was incorporated in the ﬁnal version. The updated guidelines have been reviewed by a panel of
experts so as to arrive to a consensus.
The British NICE guidelines [32] were developed by a multidisciplinary guidelines development group comprising professional
group members and consumer representatives of the main stakeholders.
126 MM. IbrahimGrading of Evidence
Majority of Egyptian recommendations were based on consensus of expert opinion. The main issue was the lack of applicability of
guidelines developed in rich countries which are mainly evidence-based to less developed societies with limited resources [164,165].
There is limited literature and clinical trials from developing countries that provide evidence based decisions. Egyptian guidelines
tried to adapt evidence-based recommendations to local economic, cultural and lifestyle circumstances. Recommended best
practice based on the clinical experience of the guidelines development group. Evidence alone is never sufﬁcient to make clinical
decisions.Size of the Document
Guidelines are not intended to be a text book on hypertension. Therefore a detailed document, though it may be a useful reference,
is not practical and may be difﬁcult to implement in the everyday practice of the busy practitioner. Important limitation of
European, British and Japanese guidelines is the large size of the document. Egyptian guidelines made a compromise between a
comprehensive and reasonable size document.
Guidelines were also produced in a small pocket-size summary. Basically, the practitioner needs to know, what to do and what
not to do and how to do it in a particular situation.
Scope
While preparing guidelines, the main concern of the writing group was to address the important practical questions seen in
everyday practice. The Egyptian guidelines differ from others by avoiding theoretical discussion, controversial issues and, in
contrast to other guidelines, reference to clinical trials was kept to the minimum. More attention was paid to areas of thresholds
for diagnosis, initiation and monitoring of drug therapy. Only a brief discussion addressed hypertension in children, since this is
generally is not within the domain of general practitioner or internists.
The following areas were not covered in the Egyptian guidelines: arterial stiffness, pulse pressure, central aortic pressure, details
of assessment of target organ damage, risk assessment charts, pharmacology of antihypertensive drugs as well as the details of
management of patients with white coat, masked hypertension and secondary forms of hypertension.
Diagnostic Threshold for Hypertension: What is a Normal BP?
The risk associated with increasing blood pressure is graded and continuous. It begins as low as at 115/75 mmHg and increases
gradually without a particular threshold that might discriminate between risk and no-risk circumstances. The choice of ofﬁce
blood pressure 140/90 mmHg as the diagnostic threshold for hypertension is neither evidence-based nor universally accepted. The
Egyptian guidelines recommend a diagnostic threshold of 159/95 mmHg. The choice of 140/90 mmHg was based upon research
studies of drug trials [26–29], where the beneﬁts of treatment are out-weighted by its side effects. Blood pressure measurement
during research studies by research personnel adhering to guidelines protocol and taking necessary precautions is different from
measurements taken by practitioner in the busy everyday ofﬁce practice [26–29,32], paying little attention to details of the pro-
cedure. Blood pressure readings taken during routine ofﬁce measurements were consistently higher than research quality mea-
surements [31].
Routine ofﬁce BP of 150/95 mmHg is comparable to a research quality BP of 140/90 mmHg [18]. Research quality ofﬁce BP of
140/90 mmHg = awake ABP of 135/85 mmHg. BP measured in routine clinical practice is 10/5 mmHg higher than a research-
quality ofﬁce BP.
There is uncertainty around the current blood pressure cut-off point (140/90 mmHg), a huge number of people being misdiag-
nosed of having hypertension [26–29]. Over-diagnosis exposes people unnecessarily to considerable risk for adverse drug reactions.
There is recent evidence to support the existence of a higher cut-point for diagnosing hypertension in routine clinical practice as
seen in studies comparing ofﬁce blood pressure with ambulatory blood pressure [18,27]. The real threshold for hypertension must
be considered as ﬂexible, being higher or lower based on the total cardiovascular risk of each individual.
In developing countries with limited resources, raising the diagnostic threshold should be more cost effective than the standard
threshold of 140/90 mmHg. In high-risk patients, however, the threshold is reduced from 150/90 to 140/90 mmHg.
Risk Factors Thresholds
There is a disagreement between guidelines regarding the deﬁnition of abnormal lipid proﬁle. The recent European guidelines
(2013) deﬁnes as abnormal total cholesterol levels >190 mg/dl, LDL-C >115 mg/dl and triglycerides >150 mg/dl [166]. These
levels are at variance from earlier guidelines e.g. the WHO/ ISH (2003) deﬁnes abnormal levels for total cholesterol, LDL-C as
240 mg/dl and 160 mg/dl respectively [167]. The Japanese guidelines (2009) took an intermediate LDL-C level of 140 mg/dl [168].
Egyptian Hypertension Society Guidelines advocates the conservative WHO/LSH guidelines high levels since this might be more
cost-effective in risk stratiﬁcation and for future management. On the other hand, many guidelines did not specify the diagnostic
threshold for abnormal lipids.
The selection of waist circumference cut-off measurement deﬁning risk of abdominal obesity was different from other guide-
lines, since waist circumference threshold depends on gender, ethnic differences and geographic regions. Egyptian guidelines were
based on recent Egyptian data on deﬁnition of abdominal obesity at a cut-off of 93.5 cm for men and 92.5 cm for women [42].
Egyptian Hypertension Guidelines 127Rationale for a Diagnostic Threshold of 150/95 mmHg:
 The diagnostic threshold of 140/90 mmHg is neither evidence-based nor universally accepted.
 At the 17th World Conference of Hypertension League Council (1997), 13 out of 27 national hypertension societies stayed with
160/95 mmHg [25].
 The distress about having hypertension and possibly requiring life-long drug therapy may lead to development of anxiety
symptoms.
 The threshold of 140/90 mmHg was based upon data from research studies and drug trials where blood pressure readings were
taken for research purposes and do not actually routine ofﬁce measurements.
 Data derived from several large studies [18,169] have equated a manual (research quality) ofﬁce blood pressure of 140/90 mmHg
with a mean awake ambulatory blood pressure (ABP) of 135/85 mmHg. There was a consistent difference between the mean
awake ABP and the routine ofﬁce blood pressure greater than the usual recognized 5 mmHg (140/90 mmHg for ofﬁce blood
pressure vs. 135/85 mmHg for mean awake ABP). Blood pressure measurement in routine clinical practice seems to be at least
10/5 mmHg higher than the research-quality ofﬁce blood pressure.
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